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Executive Summary 
Introduction 
Health Problem 
The scope of this review includes complex perianal fistulas caused by Crohn’s 
disease (CD) that are refractory to conventional and/or biologic agents, or in 
patients intolerant to such treatments. CD is a chronic inflammatory condi-
tion characterised by transmural inflammation and skip lesions. It can lead 
to fibrosis and strictures or results in sinus tracts giving rise to micro perfo-
rations and fistulas [2]. Fistulas usually occur when a fissure penetrates the 
gut wall, surrounded by granulation tissue with acute and chronic inflamma-
tion [3]. The main symptoms of perianal fistulas are anal pain with defeca-
tion and associated swelling, perianal itching, bleeding, and/or discharge of 
pus or stool from cutaneous fistula openings [3-5]. According to the Ameri-
can Gastroenterological Association (AGA), fistulas can be categorised into 
simple and complex ones [1, 4].  
The highest number of CD patients is reported in the USA, Canada, and 
Europe, with prevalence rates of above 300 per 100,000 inhabitants [2]. In 
Austria, incidence rates of 11.5 per 100,000 inhabitants were estimated, with 
9.5 and 14.6 in the rural and urban areas, respectively [6]. There is a slight 
predominance of CD developing in females and in a population of ages 20-
29 years [3, 7]. Around 17% of the patients with CD develop perianal fistulas 
10 years after diagnosis with the highest risk for patients with rectal involve-
ment [8]. 
Description of Technology 
The current report focuses on allogenic mesenchymal stem cells (MSCs) in 
patients with complex perianal fistulas caused by CD. Current standard treat-
ments are associated with high recurrence rates [9]. During the actual pro-
cess, via a fine long needle, allogeneic MSCs are injected locally and distrib-
uted into the patient’s tissue adjacent to all fistula tracts and internal open-
ings [10]. Allogeneic MSCs are assumed to prevent repeating surgeries, which 
can lead to high morbidity (i.e. incontinence), and subsequently to a loss of 
quality of life (QoL). Additionally, due to their less invasive character, espe-
cially for the anal sphincter apparatus, they may prevent the need for a per-
manent stoma [2, 5]. 
Currently, there is one product “Darvadstrocel/Cx601” available. Cx601 has 
not yet received marketing authorisation. On December 15, 2017, it received 
a positive opinion from the Committee for Medicinal Products for Human 
Use by the European Medicines Agency (EMA). 
 
Methods 
The aim of this assessment was to investigate if adult human MSCs of alloge-
neic origin are more effective to increase remission rates and the QoL of CD-
patients with complex perianal fistulas. Additionally, it was investigated if 
MSCs are safer concerning adverse events in comparison to placebo, fibrin 
glue or fistula plugs.  
complex perianal 
fistulas caused by 
Crohn’s disease (CD) can 
lead to anal pain with 
defecation/perianal 
swelling or itching, 
bleeding, incontinence 
 
fistula classification by 
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A systematic literature search was conducted in four databases (Cochrane, 
CRD, Embase, Medline). The systematic search was limited to the years 2007 
to 2017, English or German language, randomized controlled trials (RCTs) 
and prospective non-RCTs for efficacy and additionally, to interventional 
single-arm studies for safety. After deduplication, overall 590 citations were 
identified, of which three studies were included for data extraction and fur-
ther analysis. A search in three clinical trials registries (ClinicalTrials.gov; 
WHO-ICTRP; EU Clinical Trials) was conducted in order to identify ongo-
ing and unpublished studies, resulting in 45 potential hits. 
 
Results 
Included studies 
Effectiveness outcomes were addressed by two RCTs [11, 12] comparing al-
logeneic MSCs to placebo. For the safety outcomes, one further single-arm 
study [13] was included.  
The two RCTs included a total of 231 patients. The single-arm study includ-
ed 24 patients. All studies included European patients. The mean age of all 
included patients was within a range of 37-41 years. The studies included 
patients based on different Crohn’s Disease Activity Index (CDAI)-scores 
ranging from ≤200 to ≤250, indicating differences in the severity of the dis-
ease at study start. In two studies, the classification of complex perianal fis-
tulas deviated from the definition of complex perianal fistulas of the AGA, 
which was used as an inclusion criteria in the PICO. 
Two studies [11, 13] administered adipose-tissue-derived MSCs, while one 
study [12] assessed bone-marrow-derived stem cells. The dosages of the stud-
ies ranged from 10 million to 120 million cells. In one study [13], a second 
dose of cells was administered in case of lacking response to the first dose. 
Two studies [11, 13] were sponsored by the manufacturer TiGenix and one 
study [12] was funded by the DigestScience Foundation, which has possible 
ties to the manufacturer (Takeda).  
Clinical effectiveness 
Both RCTs [11, 12] reported improvements in combined remission in the in-
terventional group compared to the placebo group. Only one RCT [11] report-
ed on response, however, this results were not statistically significant (p= 
0.054). None of the two RCTs reported on fistula-relapse-free-survival. The 
two RCTs used similar scores to evaluate the QoL/severity of disease of the 
patients: With regard to the Irritable Bowel Disease Questionnaire (IBDQ), 
the RCTs reported controversial results about the effect of the MSCs on QoL. 
QoL measured with the Short-form 36 questionnaire (SF-36) was reported by 
one RCT [12] and resulted in inconclusive results. With reference to the Per-
ianal Disease Activity Index (PDAI), one study showed improved severity of 
the disease from baseline to week 12, but a deterioration at week 24, while 
the second RCT showed contrasting results for both, week 12 and week 24 
compared to baseline. The RCTs reported different CDAI-scores and showed 
that the disease was more severe in patients of one study and less severe in 
patients of the other study. Overall, the results across the different scores were 
very inconclusive, indicating that MSC-therapy is not deemed to improve 
QoL or reduce severity of the disease of the patients. The overall quality of 
evidence for the effectiveness endpoints was very low. 
systematic literature 
search in 4 databases, 
590 citations after 
deduplication,  
3 studies included, 
additional search in 
clinical trials for 
ongoing studies 
evidence comparing 
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2 RCTs + 1 single-arm 
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Safety 
None of the included studies reported any cases of peri-interventional mortal-
ity. Several sever adverse events were reported in the included studies with 
anal abscesses reported the most. Across all studies severe anal abscesses oc-
curred more commonly in the MSC-groups than in the control groups. In 
contrast, severe cases of proctalgia, anal inflammation and liver abscesses were 
only reported in the control groups. The single-arm study [13] reported one 
case of pyrexia out of 24 patients and in one RCT [12] one patient of the first 
MSC-group (10 million cell dose) developed an adenocarcinoma. However, the 
correlation between the administration of the MSC-therapy and the occur-
rence of the adenocarcinoma remained unclear. The overall level of evidence 
for safety endpoints was low. 
Upcoming evidence 
There are three ongoing RCTs of allogeneic MSCs compared to placebo. Two 
of these will provide long-term follow-up effectiveness and safety data for the 
weeks 52 and 104. Thus, these RCTs will fill the current evidence gap of ef-
fectiveness and safety data beyond 24 weeks. The two RCTs are currently 
scheduled for study completion by July 2021. The third RCT will investigate 
the intravenous administration of allogeneic MSCs in patients with treatment-
resistant moderate-to-severe CD. Study completion date is expected for July 
2018. In addition to the ongoing RCTs, there is one small, single-arm, phase I 
study that will investigate allogeneic MSCs in complex or multiple perianal 
as well as rectovaginal fistulas. Study completion date is expected for March 
2025. 
Reimbursement 
Currently, the administration of allogeneic MSCs (product: Cx601) is not in-
cluded in the Austrian benefit catalogue and therefore, it is not reimbursed 
by the Austrian healthcare system. Furthermore, no list price of Cx601 is 
available yet.  
 
Discussion and Recommendation 
The available RCTs of allogeneic MSC-therapy compared to placebo report-
ed similarly positive results for combined remission and contrasting results 
for QoL and severity of the disease of the patients. RCTs comparing MSC-
therapy with therapies established in the clinical practice, such as fibrin glue 
or fistula plugs, are lacking. Information about the grading system for the 
evaluation of the severity of adverse events was also not present. Differences 
in the classification of complex perianal fistulas and different stem cell dos-
ages (range: 10-120 million cells) of the included studies might make gener-
alizability of the results more difficult. However, the study population was 
generalizable with regard to patients’ demographics and origin. Long-term 
effectiveness and safety data beyond 24 weeks were missing. Special concerns 
exist about the missing long-term outcomes for safety, as the correlation of 
allogeneic MSCs with the development of malignancies remains unanswered 
in existing clinical trials. 
Compared to existing systematic reviews, the present systematic review fo-
cused solely on the effect of allogeneic MSCs on complex perianal fistulas 
caused by CD. 
low strength of 
evidence: no cases  
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An effective and safe allogeneic MSC-therapy would have a societal impact 
because the patients concerned are in the productive stage of their lives. How-
ever, the current evidence is not sufficient to prove that allogeneic MSCs in 
patients with complex perianal fistulas caused by CD, who are refractory to 
standard medical therapy, are more effective compared to placebo therapy. 
Additionally, it remains uncertain if MSCs are safer than placebo procedures. 
New study results will potentially influence the effectiveness and safety es-
timate considerably. The re-evaluation is recommended in 2022 when further 
ongoing studies will be finished and thereby, will bring additional evidence 
for long-term effectiveness and safety beyond 24 weeks. 
 
 
  
societal impact of MSCs: 
opportunity costs 
 
current evidence not 
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placebo 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Der Fokus der vorliegenden Übersichtsarbeit liegt auf Morbus Crohn (MC)-
bedingte komplexe, perianale Fisteln bei PatientInnen, die gegenüber kon-
ventionellen und/oder biologischen Wirkstoffen refraktär oder intolerant sind. 
MC ist eine chronisch-entzündliche Darmerkrankung, die durch eine trans-
murale Entzündung und durch einen diskontinuierlichen, segmentalen Befall 
der Darmschleimhaut (sog. skip lesions) gekennzeichnet ist. Damit einherge-
hend können Fibrosen, Strikturen oder ein Sinus-Track entstehen, welche 
folglich zu Mikroperforationen und Fisteln führen können [2]. Fisteln treten 
gewöhnlich dann auf, wenn eine Fissur umgeben von Granulationsgewebe 
mit akuten und chronischen Entzündungen die Darmwand durchdringt [3]. 
Die Hauptsymptome perianaler Fisteln sind Analschmerzen mit Defäkation 
und damit verbundenen Schwellungen, perianaler Juckreiz, Blutung und/oder 
Ausfluss von Eiter oder Stuhl aus kutanen Fistelöffnungen [3-5]. Laut der 
American Gastroenterological Association (AGA) werden Fisteln als einfach 
und komplex kategorisiert [1, 4]. 
Die höchste Anzahl von MC-PatientInnen wird für die USA, Kanada und Eu-
ropa mit Prävalenzraten von über 300 pro 100.000 EinwohnerInnen berichtet 
[2]. In Österreich wird die durchschnittliche Inzidenzrate auf 11,5 pro 100.000 
EinwohnInnen geschätzt (städtische Gebiete: 14,6 und ländliche Gebiete: 9,5) 
[6]. Frauen und PatientInnen im Alter von 20-29 Jahren haben ein höheres 
Risiko an MC zu erkranken [3, 7]. Etwa 17 % der PatientInnen mit MC, im 
Speziellen PatientInnen mit rektaler Krankheitslokation, entwickeln periana-
le Fisteln 10 Jahre nach Diagnosestellung [8]. 
Beschreibung der Technologie 
MSCs sind nicht-hämatopoetische, multipotente Zellen, die entzündungshem-
mende, immunmodulatorische und fibroblast-ähnliche potentiell heilende Ei-
genschaften aufweisen. Während des eigentlichen Prozesses werden die allo-
genen MSCs über eine Nadel lokal injiziert und in das Gewebe des/der Pati-
entIn entlang aller Fistelgänge und inneren Öffnungen verteilt. Anschließend 
werden die Zellen entlang der Fistelgänge durch die äußeren Öffnungen ver-
teilt. Die optimale Dosierung von MSCs ist bisher unklar. Wiederholte In-
jektionen können für PatientInnen erforderlich sein, wenn nach der ersten 
Injektion keine Wirkung – in Form von Schließung der Fisteln – zu erken-
nen ist [10]. Derzeitige (medikamentöse und chirurgische) Standardbehand-
lungen sind mit hohen Rezidivraten verbunden [9]. Durch eine zusätzliche 
Therapie mit allogenen MSCs könnten wiederholte Operationen, die zu ei-
ner hohen Morbidität (z. B. Inkontinenz) und folglich zu einem Verlust an 
Lebensqualität führen können, verhindert werden. Darüber hinaus kann 
durch die Therapie mit allogenen MSCs aufgrund des weniger invasiven Ein-
griffs, insbesondere für den Schließmuskelapparat, die Notwendigkeit eines 
permanenten Stomas verhindert werden [2, 5]. 
Derzeit gibt es ein Produkt „Darvadstrocel/Cx601“, dass noch nicht am Markt 
zugelassen ist. Am 15. Dezember 2017 erhielt Cx601 jedoch eine positive Stel-
lungnahme des Ausschusses für Humanarzneimittel der Europäischen Arz-
neimittel-Agentur (EMA). 
komplexe, perianale 
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Methoden 
Ziel des vorliegenden Berichts war es, die Effektivität von erwachsenen, hu-
manen MSCs allogener Herkunft mit Bezug auf die Remissionsraten, die Re-
aktion und die Lebensqualität von MC-PatientInnen mit komplexen, peri-
analen Fisteln zu untersuchen. Darüber hinaus wurde Evidenz zur Sicher-
heit von MSCs im Hinblick auf unerwünschte Nebenwirkungen im Vergleich 
zu Placebo, Fibrinkleber oder Fistel Plugs zusammengefasst. 
Eine systematische Literaturrecherche wurde in vier Datenbanken (Cochrane, 
CRD, Embase, Medline) durchgeführt. Die systematische Suche beschränk-
te sich auf die Jahre 2007 bis 2017, auf randomisierte kontrollierte Studien 
(RCTs) und prospektive nicht-RCTs für die Effektivität und zusätzlich auf 
interventionelle einarmige Studien für die Sicherheit in deutscher und eng-
lischer Sprache. Nach Dedublizierung wurden insgesamt 590 Zitate identi-
fiziert, wovon drei Studien zur Datenextraktion und weiteren Analyse ein-
bezogen wurden. Zusätzlich wurde eine Suche in drei klinischen Studienre-
gistern (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Trials) durchgeführt, 
um laufende und unveröffentlichte Studien zu identifizieren. Die Suche re-
sultierte in 45 Treffern, wovon lediglich vier Studien als potentiell relevant 
eingeschätzt wurden. 
 
Ergebnisse 
Verfügbare Evidenz 
Für die Evidenz zur Effektivität wurden zwei RCTs [11, 12] herangezogen, 
die allogene MSCs mit Placebo verglichen. Für die Evidenz zur Sicherheit 
von MSCs wurde zusätzlich eine einarmige Studie [13] eingeschlossen. 
Die beiden RCTs umfassten insgesamt 231 PatientInnen. Die einarmige Stu-
die umfasste 24 PatientInnen. Alle Studien schlossen europäische PatientIn-
nen mit ein. Das durchschnittliche Alter aller eingeschlossenen PatientInnen 
lag zwischen 37-41 Jahren. In den Studien wurden PatientInnen mit Crohn’s 
Disease Activity Index (CDAI)-Punkten zwischen ≤200 und ≤250 inkludi-
ert, was auf Unterschiede in der Schwere der Erkrankung zu Beginn der Stu-
die hinweist. In zwei Studien wich die Klassifikation komplexer, perianaler 
Fisteln von der Definition komplexer, perianaler Fisteln der AGA ab, die als 
Einschlusskriterium für die PICO verwendet wurde. 
In zwei Studien [11, 13] wurde die Therapie mit MSCs aus dem Fettgewebe 
untersucht, während sich eine Studie [12] mit der Therapie mit MSCs aus 
dem Knochenmark befasste. Die MSC-Dosierungen der Studien lagen zwi-
schen 10 Millionen und 120 Millionen Zellen. In einer Studie [13] wurde eine 
zweite Dosierung von Zellen – bei fehlender Wirkung der ersten Dosierung 
– verabreicht. 
Zwei Studien [11, 13] wurden vom Hersteller TiGenix gesponsert und eine 
Studie [12] von der DigestScience Foundation, die möglicherweise Verbin-
dungen zum Hersteller (Takeda) aufweist, finanziert. 
Ziel: Wirksamkeit und 
Sicherheit von allogenen 
MSCs im Vergleich zu 
Placebo, Fibrinkleber 
oder Fistel Plugs 
systematische 
Literatursuche in  
4 Datenbanken, 
590 Zitate nach 
Dedublizierung,  
3 Studien eingeschlossen, 
zusätzliche Suche nach 
laufenden Studien in 
klinischen 
Studienregistern 
Evidenz zu MSCs im 
Vergleich zu Placebo 
2 RCTs + 1 single-arm 
Studie (n=231 + 24 pts) 
 
Alter zwischen  
37-41 Jahren 
 
CDAI-Punkte beim 
Studienstart zwischen 
≤200 und ≤250 
zwei unterschiedliche 
Stammzellentypen  
und unterschiedliche 
Dosierungen in den  
3 Studien 
Sponsoring und 
Interessenskonflikt 
Zusammenfassung 
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Klinische Wirksamkeit 
In beiden RCTs [11, 12] kam es zu einer Verbesserung der kombinierten Re-
mission in der MSC-Gruppe gegenüber der Placebo-Gruppe. Nur ein RCT 
[11] lieferte Ergebnisse zur Reaktion und zeigte eine Verbesserung der Reak-
tion in der Interventionsgruppe. Die Ergebnisse waren jedoch nicht statistisch 
signifikant (p=0,054). Keines der beiden RCTs berichtete über das Fistel-re-
zidiv-freie Überleben. In den RCTs wurden dieselben Fragebögen/Indizes zur 
Messung der Lebensqualität (QoL) bzw. des Schweregrades der Krankheit 
angewendet: Mit Bezug auf den Irritable Bowel Disease Fragebogen (IBDQ) 
zeigten die RCTs umstrittene Ergebnisse bezüglich des MSC-Therapieeffekts 
auf die Lebensqualität. Die mit dem Short-form 36-Fragebogen (SF-36) ge-
messene Lebensqualität wurde in einem RCT [12] ermittelt, wonach MSC-
Therapien zu keiner eindeutigen Verbesserung der Lebensqualität führten. 
Mit Bezug auf den Perianal Disease Activity Index (PDAI) wies eine Studie 
einen geringeren Schweregrad der Erkrankung in Woche 12 verglichen zu 
Woche 0 auf, jedoch wiederum eine Verschlechterung der Erkrankung in Wo-
che 24. Im Vergleich dazu, zeigte das zweite RCT, kontroverse Ergebnisse so-
wohl für Woche 12 als auch für Woche 24. Die RCTs präsentierten verschie-
dene Crohn’s Disease Activity Index (CDAI)-Punkte, wodurch aufgezeigt 
wurde, dass sich die Schweregrade der Erkrankung in den beiden Studien ge-
mäß des CDAI-Indexes unterschieden. Insgesamt waren die Ergebnisse der 
Fragebögen/Indizes sehr unschlüssig, was darauf hindeutet, dass eine Ver-
besserung der Lebensqualität bzw. eine Verringerung des Schweregrades der 
Erkrankung durch die MSC-Therapie nicht bestätigt werden kann. Die Ge-
samtqualität der Evidenz für die Wirksamkeitsendpunkte war sehr niedrig. 
Sicherheit 
Keine der eingeschlossenen Studien berichtete von peri-interventionellen Mor-
talitätsfällen. In den eingeschlossenen Studien wurden mehrere schwerwie-
gende, unerwünschte Nebenwirkungen aufgelistet, wovon Analabszesse am 
häufigsten auftraten. Über alle Studien hinweg kamen schwerwiegende Anal-
abszesse in den MSC-Gruppen häufiger vor als in den Placebo-Gruppen. Im 
Gegensatz dazu wurden schwerwiegende Fälle von Proktalgie, analen Entzün-
dungen und Leberabszessen nur in den Kontrollgruppen berichtet. Die ein-
armige Studie [13] berichtete, dass Pyrexie in einem von 24 PatientInnen auf-
trat und in einem RCT [12] entwickelte ein Patient der ersten MSC-Gruppe 
(10 Millionen Zellen) ein Adenokarzinom. Die Korrelation zwischen der MSC-
Therapie und dem Auftreten des Adenokarzinoms bleibt jedoch unklar. Die 
Evidenz für die Sicherheitsendpunkte war insgesamt niedrig. 
Laufende Studien 
Zurzeit gibt es drei laufende RCTs zu allogenen MSCs im Vergleich zu Pla-
cebo. Zwei davon werden langfristige Effektivitäts- und Sicherheitsdaten für 
einen Nachbeobachtungszeitraum von 52 und 104 Wochen liefern. Somit könn-
te die aktuelle Evidenzlücke zu Wirksamkeits- und Sicherheitsdaten über ei-
nen Nachbeobachtungszeitraum von 24 Wochen gefüllt werden. Der Abschluss 
beider RCTs ist derzeit für Juli 2021 angesetzt. In einem weiteren RCT wird 
die intravenöse Verabreichung allogener MSCs bei PatientInnen mit behand-
lungsresistentem, mittelschwerem bis schwerem MC untersucht. Der Ab-
schluss der Studie wird für Juli 2018 erwartet. Zusätzlich zu den laufenden 
RCTs gibt es eine kleine, einarmige Phase-I-Studie, die allogene MSCs bei 
PatientInnen mit komplexen oder multiplen perianalen, sowie rektovagina-
len Fisteln untersucht. Studienabschluss wird für März 2025 erwartet. 
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Kostenerstattung 
Aktuell ist die Behandlung mit allogenen MSCs (Produkt: Cx601) nicht im 
österreichischen Leistungskatalog enthalten und wird daher vom österreichi-
schen Gesundheitssystem nicht erstattet. Zudem ist noch kein Listenpreis 
von Cx601 verfügbar. 
 
Diskussion 
Die verfügbaren RCTs zur allogenen MSC-Therapie im Vergleich zu Place-
bo zeigten ähnlich positive Ergebnisse für kombinierte Remission und kont-
roverse Ergebnisse bezüglich der Lebensqualität und des Schweregrades der 
Erkrankung. RCTs, die MSC-Therapien mit in der klinischen Praxis etab-
lierten Therapien, z. B. Fibrinkleber oder Fistel Plugs, verglichen, fehlen. In-
formationen zur Bewertung der Schwere unerwünschter Nebenwirkungen la-
gen ebenfalls nicht vor. Die Generalisierbarkeit der Studienergebnisse könn-
te durch die unterschiedlichen Klassifizierungen komplexer, perianaler Fis-
teln und aufgrund der unterschiedlichen Stammzelldosierungen (zwischen 
10-120 Millionen Zellen) mit Schwierigkeiten verbunden sein. Jedoch be-
züglich der Demographie und Herkunft der PatientInnen war die Studien-
population generalisierbar. Evidenz zu langfristigen Wirksamkeits- und Si-
cherheitsdaten, über 24 Wochen, fehlten. Besondere Bedenken bestehen vor 
allem hinsichtlich der fehlenden Langzeitergebnisse für die Sicherheit von 
MSC-Therapien, da die Korrelation allogener MSCs mit der Entwicklung 
maligner Erkrankungen in bestehenden klinischen Studien unbeantwortet 
bleibt. 
Im Vergleich zu bestehenden systematischen Übersichtsarbeiten konzentriert 
sich der vorliegende Bericht ausschließlich auf die klinische Wirksamkeit 
und Sicherheit von allogenen MSCs bei komplexen, perianalen Fisteln, die 
durch MC verursacht wurden. 
 
Empfehlung 
Eine effektive und sichere MSC-Therapie allogener Herkunft würde zusätz-
lich gesellschaftliche Auswirkungen mit sich bringen, insbesondere da die 
meisten, betroffenen PatientInnen im berufsfähigen Alter sind. Aktuelle Evi-
denz reicht jedoch nicht aus, um zu belegen, dass allogene MSCs bei Patien-
tInnen mit MC-assoziierten komplexen, perianalen Fisteln wirksamer sind 
als Placebo. Zudem bleibt unklar, ob eine MSC-Therapie sicherer als eine 
Placebo-Prozedur ist. Neue Studienergebnisse werden möglicherweise die 
Effektivitäts- und Sicherheitseinschätzungen erheblich beeinflussen. Die er-
neute Bewertung wird im Jahr 2022 empfohlen, wenn weitere laufende Stu-
dien abgeschlossen sind und dadurch zusätzliche Evidenz für langfristige 
Daten zur Wirksamkeit und Sicherheit über 24 Wochen hinaus erbracht wer-
den können. 
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1 Scope 
1.1 PICO question 
Are adult human mesenchymal stem cells (MSCs) of allogeneic origin in 
comparison to placebo, fibrin glue or fistula plugs in patients with complex 
perianal fistulas without abscesses caused by non-active or mildly active lu-
minal Crohn’s disease (CD) more effective to increase the quality of life (QoL) 
and remission rates and safer concerning adverse events? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Second-line or add-on therapy for adult (≥18 years old) patients with complex perianal 
fistulas without abscesses caused by non-active or mildly active luminal Crohn’s disease. The 
presented fistulas are refractory to conventional and/or biologic agents for Crohn’s disease, 
or in patients intolerant to such treatments. 
Classification of the fistulas by the definition of complex fistulas of the American 
Gastroenterological Association (AGA). 
International classification of disease (ICD)-10-CM code: K50.1, Crohn’s disease of the colon, 
K60.3 anal fistulas, K60.4 rectal fistulas, K60.5 anorectal fistulas 
Contraindications/exclusions: concomitant rectovaginal or abdominal fistulas  
MeSH Terms: Ileitis terminals, Enterocolitis regionalis, Enteritis regionalis colon/rectum, 
Morbus Crohn (MC), sklerosierende chronische Enteritis 
Intervention Adult human mesenchymal stem cells of allogeneic origin administered by a single local 
(intralesional) injection. Currently, there is one agent available in Europe: 
 Alofisel® (TiGenix, Living Medicines, BE) 
MeSH Term: Mesenchymal stem cell, MSC, Cx601, Cx-601, darvadstrocel 
Control Placebo/ Sham 
Filling materials for the fistula tracts, i.e. fibrin glue, fistula plugs 
Outcomes  
Efficacy  QoL 
 Inflammatory Bowel Disease Questionnaire (IBDQ) 
 Short-form 36 questionnaire (SF-36)  
 Perianal Disease Activity Index (PDAI) 
 Crohn’s Disease Activity Index (CDAI) 
 Fistula relapse-free survival (decisive benefit for patients after three month/13 weeks of 
fistula relapse-free survival) 
 Combined remission (closure of all treated external openings that were draining at 
baseline despite gentle finger compression and absence of collections larger than 2cm of 
the treated perianal fistulas) 
 Response (closure of at least 50% of all external openings that were draining at baseline) 
Safety  Treatment-emerged adverse events 
 Severe treatment-emerged adverse events 
 Treatment-related adverse events 
 Severe treatment-related adverse events 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Study design Time duration:  
2007-2017 
Efficacy Randomised controlled trials 
Prospective non-randomised controlled trials 
Safety Randomised controlled trials 
Prospective non-randomised controlled trials 
Uncontrolled before-after study 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What are the mesenchymal stem cells and what is/are its comparator(s)? 
B0002 What is the claimed benefit of allogeneic mesenchymal stem cells in relation to the comparators? 
B0004 Who administers allogeneic mesenchymal stem cell transplantation and in what context and 
level of care are they provided? 
B0008 What kind of special premises are needed to use allogeneic mesenchymal stem cells? 
B0009 What supplies are needed to use allogeneic mesenchymal stem cells? 
B0003 What is the phase of development and implementation of allogeneic mesenchymal stem cells? 
A0020 For which indications have allogeneic mesenchymal stem cells received marketing authorisation? 
A0021 What is the reimbursement status of allogeneic mesenchymal stem cells? 
 
Health problem and Current Use 
Element ID Research question 
A0001 For which health conditions, and for what purposes are allogeneic mesenchymal stem cells used? 
A0002 What are Crohn’s disease-associated complex perianal fistulas in the scope of this assessment? 
A0003 What are the known risk factors for Crohn’s disease-associated complex perianal fistulas? 
A0004 What is the natural course of Crohn’s disease-associated complex perianal fistulas? 
A0005 What is the burden of disease for patients with Crohn’s disease-associated complex perianal fistulas? 
A0006 What are the consequences of Crohn’s disease-associated perianal fistulas for the society? 
A0024 How are Crohn’s disease-associated complex perianal fistulas currently diagnosed according to 
published guidelines and in practice? 
A0025 How are Crohn’s disease-associated complex perianal fistulas currently managed according to 
published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
A0011 How much are allogeneic mesenchymal stem cells utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of allogeneic mesenchymal stem cells on mortality? 
D0003 What is the effect of allogeneic mesenchymal stem cells on the mortality due to causes other 
than Crohn’s disease-associated complex perianal fistulas? 
D0005 How do allogeneic mesenchymal stem cells affect symptoms and findings (severity, 
frequency) of Crohn’s disease-associated complex perianal fistulas? 
D0006 How do allogeneic mesenchymal stem cells affect progression (or recurrence) of Crohn’s 
disease-associated complex perianal fistulas? 
D0012 What is the effect of allogeneic mesenchymal stem cells on generic health-related quality of life? 
D0013 What is the effect of allogeneic mesenchymal stem cells on disease-specific quality of life? 
D0011 What is the effect of allogeneic mesenchymal stem cells on patients’ body functions? 
D0016 How does the use of allogeneic mesenchymal stem cells affect activities of daily living? 
D0017 Was the use of allogeneic mesenchymal stem cells worthwhile? 
Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas 
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Safety 
Element ID Research question 
C0008 How safe are allogeneic mesenchymal stem cells in comparison to placebo? 
C0002 Are the harms related to dosage or frequency of applying allogeneic mesenchymal stem cells? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use of 
allogeneic mesenchymal stem cells? 
C0007 Are allogeneic mesenchymal stem cells associated with user-dependent harms? 
 
 
2.2 Sources 
Description of the technology 
 Hand search in the POP, AdHopHTA, and CRD databases  
for Health Technology Assessments. 
 Background publications identified in database search:  
see Section 2.3 and in an additional hand search via Google Scholar. 
 Documentation provided by the manufacturer. 
 Questionnaire completed by the submitting hospital. 
Health problem and current Use 
 Hand search in the POP, AdHopHTA, and CRD databases  
for Health Technology Assessments. 
 Background publications identified in database search:  
see Section 2.3 and in an additional hand search via Google Scholar. 
 Documentation provided by the manufacturer. 
 Questionnaire completed by the submitting hospital.  
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on the 21st and 28th December 
2017 in the following databases: 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
 Embase 
 Medline via Ovid 
The systematic search was limited to the years 2007 to 2017. It was further 
limited to randomized controlled trials (RCTs) and prospective non-RCTs for 
efficacy and interventional single-arm studies for safety. Moreover, the search 
was restricted to articles published in English or German. After deduplica-
tion, overall 590 citations were included. The specific search strategy em-
ployed can be found in the Appendix. 
Quellen: Beschreibung 
der Technologie 
Quellen:  
Beschreibung des 
Gesundheitsproblems 
systematische 
Literatursuche in  
4 Datenbanken 
Einschränkungen:  
2007-2017, 
Studiendesign,  
Englisch und Deutsch, 
590 Zitate nach 
Deduplizierung 
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Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Tri-
als) was conducted on the 8th January 2018 resulting in 45potential hits, of 
which three RCTs and one single-arm, phase I study might be relevant for 
the topic of this assessment. 
The manufacturer of the most common product (Darvastrocel/Cx601) sub-
mitted one publication which had already been identified in the systematic 
literature search. 
By hand-search, no additional publications were identified. In total 3 studies 
were included for data extraction and further analysis. 
 
 
2.4 Flowchart of study selection 
Overall, 590 hits were identified, and 3 publications selected for analysis. The 
references were screened by two independent researchers and in case of dis-
agreement, a third researcher was involved to solve the differences. The se-
lection process is displayed in Figure 2-1. 
 
Figure 2-1: Flowchart of study selection (PRISMA Flow Diagram) 
Suche nach  
laufenden Studien 
Einreichung von 
Hersteller 
insgesamt  
3 Publikationen 
identifiziert 
Literaturauswahlprozess 
Records identified through 
database searching  
(n=590) 
Sc
re
en
in
g
 
In
cl
u
d
ed
 
E
lig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 Additional records identified 
through other sources  
(n=0) 
Records after duplicates  
removed 
(n=590) 
Records screened 
(n=590) 
Records excluded 
(n=562) 
Full-text articles  
assessed for eligibility 
(n=28) 
Full-text articles excluded,  
with reasons 
(n=25) 
 other population (n=2) 
 other intervention (n=4) 
 Full text not available (n=11) 
 Not English/German (n=2) 
 Background literature (n=6) 
Studies included in 
qualitative synthesis 
(n=3) 
 RCTs (n=2) 
 Uncontrolled before-
after study (n=1) 
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2.5 Analysis 
Data from the included studies were systematically extracted into data ex-
traction tables based on study design and the research question (See Appen-
dix Table A-1 and Table A-4). The data were extracted by one researcher (SW) 
and validated for accuracy by another researcher (MS). 
Two independent researchers conducted quality appraisal; differences were 
settled via consensus. Quality appraisal was conducted with different tools, 
depending on the study design. Randomised studies were evaluated using the 
Cochrane Risk of Bias tool [14]. Single-arm case series were evaluated using 
the Institute of Health Economics (IHE) checklist [15] (see Appendix Table 
A-3 and Table A-4).  
 
 
2.6 Synthesis 
The research questions were answered in plain text format, with reference 
to Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) evidence tables included in Table 7-1 and Table A-5 and the data-
extraction tables in the Appendices (see Table A-1 and Table A-2) [16]. No 
quantitative analysis of outcomes was performed, due to limited number and 
consistency of RCTs (n=2). 
 
Datenextraktion von  
1 Autorin, Kontrolle von 
1 Autor 
Qualitätsbeurteilung: 
RCT: Cochrane Risk  
of Bias 
Single-arm: IHE checklist 
Zusammenfassung  
der Evidenz: GRADE 
 
quantitative Analyse 
nicht möglich 
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3 Description and technical 
characteristics of the technology 
3.1 Features of the technology and 
comparators 
B0001 – What are mesenchymal stem cells and  
what is/are its comparator(s)? 
MSCs are non-hematopoietic multipotent cells that can generate osteogenic, 
adipogenic, and chondrogenic cells and come with potential anti-inflamma-
tory, immunomodulatory and fibroblast-like healing properties [4, 17]. In de-
tail, MSCs claim to regulate the adaptive and innate immune systems by sup-
pression of T-cells and maturation of dendritic cells. They aim to reduce B-cell 
activation and proliferation as well as inhibit proliferation and cytotoxicity of 
natural killer (NK) cells. Additionally, MSCs aim to promote the generation 
of regulatory T-cells via soluble factors or cell-to-cell contact mechanisms, re-
duce T-cell proliferation, suppress the inflammatory infiltrates and cytokines, 
and express anti-inflammatory cytokines [9, 18]. Overall, MSCs attempt to 
provide a way of increasing the number of cells locally, in the critical phase 
of healing [5]. 
When analysing MSCs, two distinctions need to be made. First, there is a dif-
ference between allogeneic and autologous MSCs. Autologous cells seem to 
have a lower rate of rejection and better tolerability in patients. However, they 
require additional preparation steps including a fat pad or BM harvest, ex-
pansion, and occasional thawing to be ready-to use in patients. The advantage 
of allogeneic stem cells is that they are ready-to-use, as these extra steps are 
not needed. Thus, greater numbers of patients can be treated and delays in 
treatment can be impeded. However, allogeneic cells are more likely to be 
rejected or cause a rejecting antibody response than autologous MSCs. Cur-
rently, there are no relative safety and efficacy studies comparing autologous 
with allogeneic cells [9, 19, 20]. Secondly, MSCs can be derived from either 
adipose-tissue or bone-marrow (BM). Adipose-tissue-derived MSCs provide 
the advantage that they can be harvested in large quantities with minimal 
adverse effects through liposuction [5, 9]. Currently, there is a debate about 
which ones are preferably used in treating perianal CD [18]. 
So far, placebo has been used as the comparator to MSC-based therapy. The 
placebo group receives the equal doses of i.e. saline solution instead of MSCs 
[5]. Additionally, fistula closing materials, i.e. fibrin glue or fistula plugs, are 
suggested as comparator intervention, however, they may be associated with 
a high recurrence rates [information provided by submitting hospital]. 
mesenchymale 
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mit möglicher 
entzündungshemmender 
Wirkung, 
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B0002 – What is the claimed benefit of allogeneic  
mesenchymal stem cells? 
With the current standard medical and surgical treatments, durable remis-
sion rates of complex perianal fistula remain as low as 37% [9]. The MSC-
therapy claims to reduce the risk of repeated surgery and thus lead to lower 
morbidity (i.e. incontinence) and increased QoL [2, 5]. In addition, MSC-
therapy claims to reduce the risk of removal of part of the colon and/or the 
need for a permanent stoma. Proctectomy is required in 10-20% of patients 
with perianal fistulising disease [21]. MSCs aim to be a less invasive therapy 
especially for the sphincter-based fistulas, avoiding anal incontinence, recur-
rence of new fistulas, and reducing impairment caused by surgical standard 
treatment [information provided by submitting hospital]. Another potential 
benefit of the therapy with MSCs is its local mode of action, meaning that 
the local injection of MSCs might lead to fewer systemic complications, in-
cluding infections as compared to systemic therapies [2]. 
 
 
3.2 Administration, investments, personnel  
and tools required to use mesenchymal stem cells 
B0004 – Who administers allogeneic mesenchymal stem cell 
transplantation and in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use  
allogeneic mesenchymal stem cells? 
B0009 – What supplies are needed to use allogeneic  
mesenchymal stem cells? 
MSCs are administered in a multi-disciplinary setting consisting of a special-
ised surgeon, a proctologist, a gastroenterologist, and a radiologist [1, 2, 5, 22]. 
In advance of the interventional process, a pelvic magnetic resonance imaging 
(MRI) scan is required in order to guide the surgical process and to assess the 
presence of abscesses. In addition, patients have to undergo a fistula prepa-
ration visit that includes an examination under general anaesthesia (EUA), 
fistula curettage, and seton placement – if necessary, at least two weeks be-
fore the investigational administration of the MSCs. The actual intervention-
al process is conducted under general anaesthesia. For the preparations as 
well as for the actual intervention, an operating room in a specialised hospi-
tal is needed [information provided by submitting hospital]. 
During the interventional process, MSCs are injected locally and distributed 
into the patient’s tissue adjacent to all fistula tracts and internal openings. 
Subsequently, the cells are distributed along the fistula tracks through exter-
nal openings and openings of the fistula walls [10]. Therefore, a fine long nee-
dle is required. The optimal dose of MSCs administered remains unclear. Re-
peated injections may be required for patients who did not achieve closure 
of their fistula tracts after the first administration [2]. 
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3.3 Regulatory & reimbursement status 
B0003 – What is the phase of development and implementation  
of allogeneic mesenchymal stem cells? 
MSC-therapy is an emerging therapy in the field of autoimmune diseases, 
such as graft versus host disease, multiple sclerosis, systemic lupus erythe-
matosus, systemic sclerosis, and Crohn’s disease (CD). The first trial in hu-
man patients with CD was in 2003 [23]. By 2017, there were approximately 
16 trials available, of which eight trials investigated MSC-therapy in fistulis-
ing CD, including both autologous and allogeneic stem cells [20, 24]. We 
could not identify information in which countries MSCs are marketed or 
available.  
A0020 – For which indications have allogeneic  
mesenchymal stem cells received marketing authorisation? 
To date, MSCs can only be used under two regulatory statuses in Europe: 
approved clinical trial or compassionate use (refer to Regulation [EC] No. 
1394/2007 and Directive 2001/83/EC) regulated by the European Medicines 
Agency (EMA). The MSC-therapies in the United States (US) are regulated 
by the Centre for Biologic Evaluations and Research, a division of the US 
Food and Drug Administration (FDA) [5].  
Currently, there is one product “Darvadstrocel/Cx601” available. Cx601 has 
no marketing authorisation. However, on December 15, 2017, it received a 
positive opinion from the Committee for Medicinal Products for Human Use 
(CHMP) of the EMA. It is the first allogeneic stem cell therapy in Europe that 
received a positive CHMP opinion. The company expects marketing approv-
al of Cx601 for February 2018 [information provided by the manufacturer]. 
A0021 – What is the reimbursement status  
of allogeneic mesenchymal stem cells? 
The administration of allogeneic MSCs (Cx601) is not included in the Aus-
trian benefit catalogue, therefore, it is not reimbursed by the Austrian health 
care system. Furthermore, no list price of Cx601 is available. 
 
 
MSC-Therapie bei 
Autoimmunkrankheiten, 
2003 erste Studie mit 
Morbus Crohn (MC) 
PatientInnen,  
16 Studien bis 2017 
Verwendung von  
MSCs in Europa als 
zugelassene, 
medizinische Studie 
oder in Spezialfällen 
keine Markzulassung  
für Darvadstrocel/Cx601, 
Hersteller erwarten 
Markzulassung für 
Februar 2018 
keine Finanzierung  
von Cx601 in Österreich, 
kein Listenpreis 
verfügbar 

 LBI-HTA | 2018 25 
4 Health Problem and Current Use 
4.1 Overview of the disease or health condition 
A0001 – For which health conditions, and  
for what purposes are allogeneic mesenchymal stem cells used? 
A0002 – What is the disease and health condition in the scope  
of this assessment? 
The scope of this assessment includes complex perianal fistulas caused by 
CD that are refractory to conventional medication and/or biologic agents, or 
in patients intolerant to such treatments [11]. 
CD is a chronic inflammatory condition characterised by transmural in-
flammation and skip lesions. CD may lead to fibrosis and strictures or result 
in sinus tracts giving rise to micro perforations and fistulas [2]. Fistulas 
usually occur when a fissure penetrates the gut wall surrounded by granula-
tion tissue with acute and chronic inflammation [3]. 
Perianal fistulas can be classified with the Park’s classification of fistulas. It 
distinguishes between the following fistula tracts [4]: 
 Inter-sphincteric: The fistula tract travels along the inter-sphincteric 
plane to the perianal skin [7, 25]. It occurs in 20-45% of the cases [9]. 
 Trans-sphincteric: The fistula tract encompasses a portion of the in-
ternal and external sphincter or the puborectal muscle and terminates 
on the skin overlying the buttocks [7, 25]. It accounts for 30-60% of 
the cases [9]. 
 Supra-sphincteric: The fistula tract runs upwards in the inter-sphincter-
ic space, then downwards crossing the levator ani muscle, subsequent-
ly, reaching the perianal skin [25]. It occurs in 20% of the cases [9]. 
 Extra-sphincteric: The fistula tract extends from an internal opening 
in the bowel proximal to the anus, encompasses the entire sphincter 
apparatus, and opens onto the skin overlying the buttocks [7]. It ac-
counts for 2-5% of the cases [9]. 
 Superficial: The fistula tract does not involve the sphincter complex 
[25]. 
According to the American Gastroenterological Association (AGA), perianal 
fistulas are distinguished into simple and complex ones [1, 4]:  
 Simple perianal fistulas are characterised as low fistulas that include 
inter-sphincteric and trans-sphincteric fistulas with the internal open-
ing at or below the dentate line. They have a single external opening, 
and are not associated with proctitis, rectovaginal fistulas or anorec-
tal strictures. 
 Complex perianal fistulas include the following characteristics: 
 High fistulas involve at least one-third of the external anal sphinc-
ter. They include inter-sphincteric fistulas with high secondary ex-
tensions, trans-sphincteric fistulas with the internal opening above 
the dentate line, supra-sphincteric and extra-sphincteric fistulas.  
 Possible multiple external openings. 
 Possibly associated with present perianal abscesses, rectovaginal 
fistulas, anorectal strictures, or active rectal disease at endoscopy. 
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A0003 – What are the known risk factors  
for Crohn’s disease-associated complex perianal fistulas? 
The risk factors of the underlying disease, CD, and thus, the cause of perianal 
fistulas include: 
 Gender: There is a slight female predominance, meaning that hormo-
nal factors might play a role [7]. 
 Genetic: CD is more common in those of Ashkenazi Jewish ethnicity 
than in non-Jews. However, ethnic and racial differences may be re-
lated to environmental and lifestyle factors in addition to underlying 
genetic differences. Hereditary predisposition can be emphasised as 
approximately 10-25% of individuals with CD have a first degree rel-
ative with the disease [7]. Most strongly CD-associated genes include 
CARD15, IBD5 locus, autophagy genes like ATG16L1 and IRGM, and 
interleukin (IL)-23 receptor [26]. 
 Smoking: Nicotine and/or smoking by-products may directly affect 
mucosal immune responses, smooth muscle tone, gut permeability, 
and microvasculature. Current and past smoking is associated with 
increased risk of CD as well as with the recurrence of CD [7]. 
 “Western” style diet: Fried and sugary foods are associated with in-
creased risk of developing CD [7]. 
 Antibiotic exposure, particularly tetracyclines, are associated with an 
increased risk of CD [information provided by the external reviewer]. 
 Psycho-social factors: Stress may have a role in exacerbating the symp-
toms in patients with CD, possibly through activation of the enteric 
nervous system and the elaboration of pro-inflammatory cytokines [7]. 
Risk factors for developing perianal fistulas caused by CD involve: 
 Race: Non-Caucasians and those of Sephardic Jewish ethnicity with 
CD have a higher risk of perianal disease [7].  
 Age at diagnosis: CD patients who are younger than 40 years of age 
have a greater risk of perianal disease [3, 7]. 
 Disease location: Patients with colonic (41%) [rectal (91%)] or  
ileocolonic CD have a higher risk of perianal disease [3, 7, 25].  
 Presence of abscesses and intestinal strictures [3]. 
A0004 – What is the natural course of Crohn’s disease-associated 
complex perianal fistulas? 
The natural course of CD is deemed to be both, relapsing and remitting. CD 
is most commonly diagnosed in a population of 20-29 years of age. Approx-
imately 17% of patients with CD develop perianal fistulas 10 years after di-
agnosis, especially in patients with rectal involvement. A recent study inves-
tigated the mortality and causes of death in CD and reported that there was 
no significant difference in overall mortality as well as cause-specific mortal-
ity (gastrointestinal cancer, cancer and heart disease) between CD patients 
and healthy patients [8]. However, CD leads to high morbidity (i.e. pain and 
incontinence) and thus, reduces the QoL of the patients. Due to the high re-
currence rates of current standard medical and surgical treatments, addition-
al therapies are needed, especially for high refractory patients. 
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4.2 Effects of the disease or health condition 
on the individual and society 
A0005 – What is the burden of disease for patients with Crohn’s disease-
associated complex perianal fistulas?  
The presence of complex perianal fistulas negatively impacts the QoL of the 
patients, particularly, due to anal pain with defecation and associated swell-
ing, perianal itching, bleeding and/or discharge of pus or stool from cutane-
ous fistula openings, as well as in some cases due to faecal incontinence [3-
5]. Besides, additional problems induced by perianal fistulas such as second-
ary infections, abscess formations, organ system function impairment, and 
high disability rates can occur [18]. About one-third of the patients with CD-
associated perianal fistulas are non-responders to standard medical treat-
ments, what makes the treatment of perianal fistulas more complicated [5].  
A0006 – What are the consequences of Crohn’s disease-associated 
perianal fistulas for the society? 
In general, CD incidence rates are higher in more developed countries [12]. 
In particular, younger age is associated with higher incidence of CD. The 
highest number of incidents of CD was described in the population of young 
adults, between 20 and 29 years of age, with 16.6 cases per 100,000 person-
years [7]. When it comes to CD-associated perianal fistulas, the cumulative 
incidence is 12% after one year and this doubles 20 years after diagnosis [25]. 
CD has a negative impact on patients’ work, social, and sexual lives. Conse-
quently, this and the fact of increasing incidence rates of perianal fistulas in 
CD patients leads to additional societal costs [information provided by sub-
mitting hospital]. 
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identify clinically “silent” abscesses and luminal inflammation. Addi-
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fibrotic tissues.  
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 Endoanal ultrasound (EUS) is a useful alternative to MRI conducted 
by a coloproctologist. However, its accuracy can be limited by the re-
stricted view. Using hydrogen peroxide may enhance fistula tracts, 
thereby improving their identification and image definition [3, 25].  
In addition, the following diagnostic can be used: 
 Endoscopy is used for the assessment of the rectum to determine the 
most appropriate surgical management strategy [25]. 
 Transcutaneous perineal ultrasound (TPUS) is another simple and 
accurate diagnostic method for the classification of perianal fistulas 
in CD, for the preliminary assessment as well as for the follow-up of 
the perianal CD. However, TPUS is limited by its narrow view in iden-
tifying deep abscesses [3]. 
 Fistulography is an internal diagnostic imaging technique performed 
by an interventional radiologist to determine the characteristics of a 
fistula. It results in poor accuracy, however, it can provide additional 
information in some exceptionally complex fistulas. Fistulography is 
limited by the exposure to radiation during the intervention [25]. 
In case that perianal disease is the initial presentation of CD, it can be diffi-
cult to distinguish it from haemorrhoids, fissures, and fistulas seen in patients 
who do not have CD. Features, such as the location other than the posterior 
midline, the presence of multiple, recurrent, or non-healing fissures, fissures 
that are asymptomatic suggest CD-associated fistulas [7]. 
A0025 – How are Crohn’s disease-associated complex perianal fistulas 
currently managed according to published guidelines and in practice? 
In the first step, the diagnosis of CD-associated perianal fistulas should be 
followed by immediate damage control policies including treatment of local 
infection, usually by use of antibiotics (combination of ciprofloxacin and me-
tronidazole). In addition, perianal abscesses should be drained with non-cut-
ting seton placements in order to control infections, as setons allow a contin-
uous draining of the fistula tract [1, 4]. The choice of medical treatments de-
pends on the location of the disease, its severity, and the response to earlier 
therapies [28]. Generally, the standard medical therapy consists of a first-line 
anti-TNF-therapy in combination with further antibiotics and/or immuno-
suppressants, which are explained in more detail below: 
 Anti-TNF-therapy is recommended by European Crohn’s and Colitis 
Organisation (ECCO) guidelines as first-line medical therapy for in-
duction and maintenance therapy in a patient with complex perianal 
fistulas caused by CD. Infliximab (IFX) presents the only anti-TNF-
agent claimed to be effective in closing complex perianal fistulas [4]. 
Another anti-TNF agent, adalimumab, is also moderately effective for 
the induction and maintenance of fistula closure [1, 9, 25, 28]. 
 Antibiotics should be added to medical and surgical treatments to avoid 
local sepsis and to maintain clinical response. In fact, antibiotics in as-
sociation with anti-TNF-agents or immunosuppressants are meant to 
enhance the effect of these medications [4]. Therefore, antibiotics are 
part of the first-line management with anti-TNF-agents [1]. 
 Immunosuppressants, such as thiopurines or thalidomide, are used for 
the treatment of active fistulas. However, long-term use of immuno-
modulators is limited due to their toxicity [3, 25]. 
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If there is no clinical response to medical treatments, there are three further 
options available (see Figure 4-1) [1, 2, 5]: 
1. Consider a change of the biologic such as a new anti-TNF-agent. 
2. Reassess and consider surgical options (further detail below). 
3. Consider local therapy such as MSC-therapy. 
Surgical treatments are administered after imaging techniques and endoscopy 
had outlined the anatomy of fistulas [4]. The following surgical interventions 
are available: 
 Mucosal advancement flap (MAF) presents a surgical treatment op-
tion for the closure of internal fistula openings [25]. It involves the 
mobilisation of a rectal mucosal flap of tissue (mucosa, submucosa or 
circular muscle) to cover the internal opening of the fistula tract, leav-
ing the anal sphincter complex untouched [21]. 
 Ligation of the inter-sphincteric fistula tract (LIFT) is a surgical op-
tion in the management of trans-sphincteric fistulas. The procedure 
is based on ligation of the fistula tract in the inter-sphincteric space, 
thereby, severing communication between the fistula and the anal ca-
nal lumen, and excision of the presumed source of the fistula, the inter-
sphincteric anal gland. Within the inter-sphincteric space, one suture 
is used to ligate the fistula tract at the level of the internal anal sphinc-
ter. Once the fistula tract passing through the external anal sphincter 
and the buttock are debrided of granulation tissue, another suture is 
used to ligate the fistula at the level of the external anal sphincter [in-
formation provided by the external reviewer]. 
 Fistula plugs are cone-shaped plugs synthesized from lyophilized por-
cine small intestine mucosa that are threaded through the fistulous 
tract and fixed in place with a suture. As a result, the fistula tracts are 
filled by leaving the sphincter apparatus untouched [29].  
 Fibrin glue consists of fibrinogen and thrombin with which a fibrin 
clot is formed to stimulate wound healing by inducing angiogenesis 
and fibroblast growth [21, 25, 29]. 
 Diverting temporary stoma is an artificial bowel outlet, also called osto-
my. It presents an option for patients with severe perianal sepsis with 
insufficient response to a seton placement, or as a temporary measure 
to improve the condition of the patient until complete induction of 
medical therapy or proctectomy [21]. 
 Proctectomy (with a permanent stoma) is a surgery to remove all or 
part of the rectum and often the last resort in severe, therapy-refrac-
tory fistulising disease, especially in CD patients with complex fistu-
las associated with uncontrollable and debilitating abscesses, recur-
rent sepsis, colonic or perianal disease, refractory proctitis, or anal ste-
nosis [3, 25]. 
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All surgical interventions have high recurrence rates in common and an in-
creased risk of a permanent stoma. The boundaries of current therapies sug-
gest MSC-therapy as an ultima-ratio add-on therapy to standard medical ther-
apies in patients who are refractory to either anti-TNF-agents (i.e. infliximab) 
as first-line therapy alone or in combination with antibiotics and/or immu-
nomodulators [26]. Biologics and/or immunomodulators are given to control 
luminal disease and perianal inflammation, while MSCs are meant to close 
any residual fistulas [5]. In addition, MSC-therapy can also be administered 
to patients who have not yet used anti-TNF-agents and immunomodulators 
or in whom the perianal fistulising disease is the main or only manifestation 
of the CD. Thereby, the patients could avoid the risk of systemic immuno-
suppression by undergoing stem cell therapy [2]. 
 
Figure 4-1: Clinical management algorithm for the treatment of perianal fistulas 
caused by Crohn’s disease (Source: [1]) 
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4.4 Target population 
A0007 – What is the target population in this assessment? 
In this assessment, the target population includes patients with perianal com-
plex fistulas caused by non-active or mildly active luminal CD that are re-
fractory to standard medical treatments involving anti-TNF-agents alone or 
in combination with antibiotics and/or immunomodulators, or in patients in-
tolerant to such treatments. Patients with simple perianal or rectovaginal fis-
tulas were excluded from this assessment. 
A0023 – How many people belong to the target population?  
In the USA, Canada, and Europe the highest prevalence rates have been re-
ported with above 300 per 100,000 people [2]. In Austria, incidence rates of 
11.5 per 100,000 inhabitants were estimated, with 9.5 and 14.6 in the rural 
and urban areas, respectively [6]. In general, approximately, 17% and 24% 
of patients with CD develop perianal fistulas at 10 and 20 years after diag-
nosis, respectively. In particular, patients with rectal involvement (92%) de-
velop perianal fistulas. Approximately 45% of the patients diagnosed with 
perianal disease, develop the fistulas before being diagnosed with CD and 
about 70-80% of the patients suffer from complex perianal fistulas [2, 7]. The 
majority of the patients (60-70%) are refractory to conventional medical treat-
ments [2]. 
A0011 – How much are allogeneic mesenchymal stem cells utilised? 
The previous administrations of MSCs in patients with CD-associated com-
plex perianal fistulas have been within the scope of approval studies. There-
fore, an estimate on the number of current and potential/expected utilisation 
of MSCs in complex perianal fistulas is not yet available for Austria.  
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as critical to derive a recommendation: 
 Quality of life (QoL) measured with: 
 Inflammatory Bowel Disease Questionnaire 
 Short-form-36 score 
 Perianal Disease Activity Index 
 Crohn’s Disease Activity Index 
 Combined remission 
 Response 
The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item ques-
tionnaire filled in by patients including four categories: bowel function, emo-
tional status, systemic symptoms, and social functioning. It does not include 
a special category for perianal CD. The total score on this index ranges from 
32 to 224, with higher scores indicating better QoL. The score of patients in 
remission is between 170 and 190 [30]. 
The Short-form-36 (SF-36) score is a multi-item generic health survey filled 
in by patients including eight health domains: physical functioning, role phys-
ical functioning, bodily pain, general health, vitality, social functioning, emo-
tional role, and mental health. The questionnaires are not specially formed 
for CD. The response scales for the SF-36 items vary across and within the 
scales with the number of response options ranging from 3 (for physical func-
tioning) to 6 (for vitality and mental health). The scores are calculated by 
summing the responses across scale items and then transforming these raw 
scores to a 0–100 scale, with higher scores indicating better QoL [31]. 
The Perianal Disease Activity Index (PDAI) is a scoring system for clinicians 
to evaluate the severity of perianal CD, with lower scores indicating more 
severe disease. The score includes five items: discharge, pain, restriction of 
sexual activity, type of perianal disease, and degree of induration. Thus, it 
includes a special category for fistulising disease. Each item is graded on a 5-
point Likert scale ranging from score 0 (no symptoms) to score 4 (severe symp-
toms) [30]. 
The Crohn’s Disease Activity Index (CDAI) is a scoring system for clinicians 
to evaluate the severity of the disease, involving eight categories: the number 
of liquid stools, abdominal pain, general well-being, extraintestinal compli-
cations, antidiarrheal drugs, abdominal mass, and haematocrit body weight. 
A special category for the fistulising disease is not included. The score rang-
es from 0 to 600, with lower scores indicating less experienced severe disease. 
The limit between active and very severe disease was defined as a cut-off val-
ue of 450 points. CDAI scores of 220–450 were labelled as moderately active 
disease and scores of 150–219 as a mildly active disease [30]. 
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Combined remission is characterised as the closure of all treated external 
openings that were draining at baseline despite gentle finger compression, 
the absence of discharge in all individual fistulas, and/or the absence of col-
lections larger than 2cm determined by MRI. In the literature, the combina-
tion of the last two criteria is also referred to as fistula healing of all individ-
ual fistulas [11, 12]. 
Response is characterised as the closure of at least 50% of all treated external 
openings that were draining at baseline [11, 12]. The definition of response 
was chosen from the biggest RCT available with 200 patients. 
Fistula relapse-free survival, defined as the length of time patients survive 
without any signs or symptoms of returning and/or new fistulas after prima-
ry stem cell treatment for CD-associated perianal fistulas. According to ex-
pert opinions, a decisive benefit for patients results as of 13 weeks of fistula 
relapse-free survival [information provided by submitting hospital]. This end-
point was deemed important, but not crucial to derive a recommendation. 
 
 
5.2 Included studies 
To evaluate the effectiveness of allogeneic MSCs, we included two randomised 
controlled trials (RCTs) [11, 12] comparing allogeneic MSCs with placebo. 
Study characteristics 
The two RCTs were conducted in Spain, Belgium, Austria, Canada, Germany, 
France, Italy, Israel [11] and in the Netherlands [12]. The studies were spon-
sored by the manufacturer TiGenix and by the Digest Science Foundation, 
respectively. In both studies, the length of follow-up was 24 weeks. Long-term 
comparative data beyond 24 weeks is currently not available. 
The two RCTs investigated different types of MSCs, namely ASCs [11] and 
BM-MSCs [12]. In Panés et al. [11], 120 million cells were administered in 
the interventional group for a maximum of three fistula tracts and 24 mL sa-
line solution (placebo) in the control group. In comparison, the study of Mo-
lendijk et al. [12] investigated three different doses of BM-MSCs: (1) 10 mil-
lion, (2) 30 million and (3) 90 million cells compared to placebo, defined as 
0.9% NaCI/5% human albumin solution. 
Patient characteristics 
Panés et al. included 212 patients, of which 107 belonged to the interventional 
group and 105 to the control group. Of the 212 patients, 41 (19.3%) were lost 
to follow-up. Molendijk et al. included 21 patients in their study. Five pa-
tients in each of the three interventional groups and six patients in the con-
trol group. No patients were lost to follow-up. 
The mean age of the patients was around 38 years in both RCTs ranging 
from 33.4 to 40.8 years across the different treatment groups. 
kombinierte Remission: 
Verschluss von allen 
nässelnden,  
behandelten Fisteln, 
keine Kollektionen >2 cm 
Reaktion: Verschluss 
von zumindest 50 % der 
behandelten Fisteln 
wichtiger Endpunkt: 
Fistel-rezidiv-freies-
Überleben: 
ausschlaggebender 
Nutzen ab 13 Wochen 
MSCs vs. Placebo:  
2 RCT inkludiert 
1 multinationales RCT, 
1 RCT aus den 
Niederlanden, 
Nachuntersuchungen 
bis 24. Woche 
1 RCT: 120 Millionen 
MSCs aus Fettgewebe, 
1 RCT: 3 verschiedene 
MSC-Dosierungen aus 
Knochenmark 
1 RCT: 212 pts,  
41 davon vollendeten  
24 Wochen nicht, 
1 RCT: 21 pts, 5 pts pro 
Therapiegruppe,  
6 pts in Kontrollgruppe 
 
durschnittliches Alter 
beider RCTs: 38 Jahre  
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Both RCTs had the same inclusion criteria except the CDAI-score and the 
categorisation of the fistula tracts. In Panés et al., the patients included had 
a CDAI score ≤220, indicating non-active or mildly active luminal CD, and 
complex perianal fistulas, defined by the AGA guidelines. In comparison, Mo-
lendijk et al. included patients with a CDAI score ≤250 and with actively 
draining perianal fistulas with one to two internal openings and one to three 
fistula tracts. The definition for complex perianal fistulas applied by Mo-
lendijk et al. did not correspond to the AGA guidelines. Non-complex fistu-
las were also included in their study, although described as complex. There 
was homogeneity with regard to exclusion criteria, except for pregnancy and 
breastfeeding, renal or hepatic failure, change in concomitant medication, 
documented human immunodeficiency virus infection, active hepatitis B, C, 
or tuberculosis, malignancy within the past five years and a history of lym-
phoproliferative disease, which were only considered in Molendijk et al. 
Detailed patient and study characteristics of included studies are displayed 
in Table A-1. 
 
 
5.3 Results 
Treatment effect on mortality 
D0001 – What is the expected beneficial effect  
of allogeneic mesenchymal stem cells on mortality? 
D0003 – What is the effect of allogeneic mesenchymal stem cells  
on the mortality due to causes other than Crohn’s disease-associated 
complex perianal fistulas? 
No evidence was found to answer the research question. None of the included 
studies reported cases of overall or disease-specific mortality, neither in the 
treatment group nor the placebo arm. 
 
Treatment effect on morbidity 
D0005 – How do allogeneic mesenchymal stem cells affect symptoms 
and findings (severity, frequency) of Crohn’s disease-associated complex 
perianal fistulas? 
This research question was answered in the section “Health-related quality 
of life”. 
D0006 – How do allogeneic mesenchymal stem cells affect progression 
(or recurrence) of Crohn’s disease-associated complex perianal fistulas? 
Combined remission 
Both RCTs reported a significant improvement in combined remission in the 
interventional group compared to the placebo arm: Panés et al. [11] reported 
50% (n=107) versus 34% of the patients (n=105) achieving combined remis-
sion after 24 weeks (mean difference 15.2%, CI 0.2-30.3, p=0.024). For the 
second interventional group (30 million cell dose), Molendijk et al. [12] re-
ported the highest percentage (80%) of the patients (n=5) achieving combined 
remission compared to 33.3% of the patients (n=6) in the control arm after 12 
weeks (p=0.06). The percentages of patients with combined remission in the 
other interventional groups were lower (IG1: 40%, n=5, and IG3: 20%, n=5). 
Unterschiede in 
Einschlusskriterien: 
CDAI-Punkte, 
Fistelklassifizierungen 
abweichend von  
AGA-Definition 
 
 
1 RCT: zusätzliche 
Ausschlusskriterien,  
z. B. Schwangerschaft, 
Hepatitis C, Malignität 
in den letzten 5 Jahren, 
etc. 
keine Evidenz  
zur Gesamt- und 
krankheitsspezifischen 
Mortalität 
Referenz zu “Health-
related quality of life” 
1 RCT: signifikant 
verbesserte kombinierte 
Remission, 
1 RCT: signifikant 
verbesserte kombinierte 
Remission in  
1/3 der MSC-Gruppen 
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Response 
Panés et al. [11] reported that 66% of the 107 patients receiving stem cells 
responded to the treatment1, compared to 53% of the 105 patients who re-
ceived placebo. However, this effect was not statistically significant (p=0.054). 
The RCT of Molendijk et al. did not report response rates. 
Relapse-free survival 
With regard to the outcome fistula relapse-free survival, none of the two in-
cluded RCTs [16, 19] reported the percentage of patients who were relapse-
free 13 weeks after the intervention. 
 
Health-related quality of life 
D0012 – What is the effect of allogeneic mesenchymal stem cells  
on generic health-related quality of life? 
D0013 – What is the effect of allogeneic mesenchymal stem cells  
on disease-specific quality of life? 
Different QoL scores, namely the (s)IBDQ, the SF-36, the PDAI, and the CDAI, 
were reported to evaluate this research question. 
(s)IBDQ 
The RCTs used different versions of the IBDQ questionnaire: Panés el al. 
[11] used the IBDQ and reported similar improvements in QoL-scores from 
baseline to week 24 in the treatment group and control group. In compari-
son, Molendijk et al. [12] used the short-form IBDQ and reported the best 
QoL-improvement in the control group, while there was worsening QoL in 
the first and third interventional group (10 and 90 million cell dose), and on-
ly a slight improvement in interventional group 2 (30 million cell dose) from 
baseline to week 24.  
SF-36 
Solely Molendijk et al. [12] reported SF-36 scores for week 0 and 24 in their 
RCT, which yielded very inconclusive results. For physical functioning, im-
provements were reported in all groups, with the highest improvement in the 
second interventional group (30 million cell dose), while for physical role func-
tioning worsening QoL in all interventional groups and a slight improvement 
in QoL in the control group was reported. With regard to bodily pain, wors-
ening QoL was shown for the first and second interventional group (10 and 
30 million cell doses), while QoL improvements were shown for the third in-
terventional (90 million cell dose) and the control group. For general health 
perceptions all groups led to worsening QoL and for vitality, only the second 
interventional group (30 million cell dose) reported a slight improvement in 
QoL. For social functioning, emotional role functioning and mental health 
the results were very heterogeneous. 
                                                             
1 Defined as a closure of at least 50% of all treated external openings, after 24 weeks. 
1 RCT: höhere 
Reaktionsrate in  
MSC-Gruppe als in 
Kontrollgruppe,  
nicht signifikant 
Fistel-rezidiv-freies-
Überleben wurde in 
keinem der RCTs 
berichtet 
unterschiedliche Indizes 
zur Messung der 
Lebensqualität 
 
IBDQ: 1 RCT: ähnliche 
Lebensqualitäts-
verbesserungen 
zwischen Gruppen, 
1 RCT: stärkere 
Verbesserungen in der 
Kontrollgruppe, 
MSCs kein 
beweiskräftiger Effekt 
auf Lebensqualität 
SF-36: 
1 RCT: kontroverse 
Ergebnisse:  
z. B. Lebensqualität-
verbesserung bezüglich 
physischen Funktionen 
vs. Lebensqualität-
verschlechterung 
bezüglich allgemeinen 
Gesundheits-
wahrnehmungen 
Clinical effectiveness 
LBI-HTA | 2018 37 
PDAI 
Panés et al. [11] showed that the disease of the patients was less severe in 
week 12 compared to baseline, with better improvements in the interventional 
group, but a worsening disease at week 24. In comparison, Molendijk et al. 
[12] showed that the severity of the disease of the patients of the interven-
tional group was lower at week 12, but not in patients of the control group. 
Inconclusive effects on the severity of the disease were reported at week 24. 
CDAI 
Both RCTs also reported CDAI scores: Panés et al. [11] showed a worse se-
vere disease of the patients at week 24 compared to baseline for both groups, 
however, a less worsening for the control group. In detail, this holds true for 
the categories general wellbeing and abdominal pain, while there was a slight 
reduction in the number of liquid stools in the interventional group. In com-
parison, Molendijk et al. [12] reported less severe disease at week 24 com-
pared to baseline in all groups, but the third interventional group (90 million 
cell dose), with the highest improvement in the second interventional group 
(30 million cells dose).  
In total, across the different scores, results were very inconclusive in both 
studies [11, 12]. Therefore, MSCs are not deemed to improve QoL of the pa-
tients.  
Non of the two RCTs reported significance levels for the QoL-scores. Specif-
ic improvements or deteriorations in the scores are listed in the GRADE Ta-
ble 7-1. An overview of all results of the RCTs are displayed in Table A-1. 
 
Function 
D0011 – What is the effect of allogeneic mesenchymal stem cells on 
patients’ body functions? 
D0016 – How does the use of allogeneic mesenchymal stem cells affect 
activities of daily living? 
The effect of MSC-therapies on patients’ body functions was illustrated with 
different QoL scores. Overall, both studies [11, 12] reported very inconclusive 
results across the different scores. Consequently, MSC-therapy is not deemed 
to improve QoL of the patients. However, it seemed that there might be small 
improvements in physical functioning (i.e. number of liquid stools), social 
functioning and mental health.  
 
Patient satisfaction 
D0017 – Was the use of allogeneic mesenchymal stem cells worthwhile? 
Based on the improved remission data, MSC-therapy might be worthwhile 
for patients. However, if remission has no impact on patients QoL and based 
on the reported, very inconclusive QoL-data, the question, if MSC-therapy is 
worthwhile for patients, remains unclear. 
 
PDAI: 1 RCT: 
schwerwiegendere 
Krankheit nach  
24 Wochen, 1 RCT:  
keine beweiskräftigen 
Ergebnisse in MSC-
Gruppen in 24. Woche 
CDAI: 1 RCT: 
Verschlechterung des 
Krankheitsschweregrades 
in 24. Woche, 
1. RCT: Verbesserung  
des Schweregrades nach 
24 Wochen  größte 
Verbesserung in  
MSC-Gruppe 2 
Verbesserung der 
Lebensqualität durch 
MSCs nicht sicher 
keine  
Signifikanzniveaus für 
Lebensqualitätdaten 
keine beweiskräftigen 
Ergebnisse, jedoch 
mögliche 
Verbesserungen in 
physischen und sozialen 
Funktionen und in 
psychischer Gesundheit 
unklar ob MSCs  
für PatientInnen 
lohnenswert sind 
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6 Safety 
6.1 Outcomes 
The following outcome was defined as critical to derive a recommendation: 
 Severe treatment-related adverse event 
Severe treatment-emerged adverse events and treatment-related adverse events 
were deemed important, but not crucial to derive a recommendation. 
In accordance with the EUnetHTA guidelines on safety outcomes, adverse 
events are defined as “any untoward medical occurrence, unintended disease 
or injury or any untoward clinical signs (including an abnormal laboratory 
finding) in subjects, users or other persons whether or not related to the inves-
tigational medical device” [32]. Adverse events, including (severe) treatment-
emerged adverse events and (severe) treatment-related adverse events, which 
may occur during or shortly after the intervention or during follow-up, are 
the most common safety issues associated with the MSC-administration and 
the comparator interventions. The most frequently reported adverse events 
have been described. 
 
 
6.2 Included Studies 
For the safety evaluation of the MSC-administration, two RCTs and one pro-
spective interventional single-arm study were included. The two RCTs [11, 
12] have already been described in the previous section (Clinical Effective-
ness, 5.2.). De la Portilla et al. [13] investigated the administration of alloge-
neic ASCs in 24 patients with complex perianal fistulas caused by CD. 
Study characteristics 
The single-arm study [13] was conducted in Spain and sponsored by the man-
ufacturer TiGenix. The study did not report any competing interests. The 
length of the reported follow-up was 24 weeks. 
De la Portilla et al. [13] assessed the safety and efficacy of allogeneic ASCs 
in patients with CD-associated complex perianal fistulas. During the first 
administration, 20 million cells were injected in one draining fistula tract. If 
fistula closure was not complete at week 12, the second administration of 40 
million cells was performed. 
With regard to safety outcomes, treatment-emerged adverse events and (se-
vere) treatment-related adverse events were reported. However, information 
about the grading system for the evaluation of the severity of adverse events 
was lacking. 
 
 
kritischer Endpunkt: 
schwerwiegende 
behandlungsbedingte 
Nebenwirkungen (NW) 
NW definiert gemäß 
den EUnetHTA 
Leitlinien 
Sicherheit: 2 RCTs &  
1 zusätzliche einarmige 
Studie (n=24 pts) 
einarmige Studie  
aus Spanien, 24 Wochen 
Nachuntersuchungen 
Effektivität und 
Sicherheit von MSCs  
aus Fettgewebe 
keine Informationen  
zur Evaluierung der 
Schweregrade der NW 
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Patient characteristics 
The study of de la Portilla et al. [13] included 24 patients (full analysis) with 
complex perianal fistulas caused by CD that underwent the administration 
of ASCs. Of the 24 patients, eight patients prematurely withdrew from the 
study, thus, 16 patients completed the study period of 24 weeks. The mean 
age of the 24 patients was 36 years. Unlike to the RCTs that included pa-
tients with a CDAI-score of ≤220 [11] and ≤250 [12], the single-arm study 
[13] included patients with non-active luminal CD defined by a CDAI ≤200. 
With regard to the classification of the fistulas, de la Portilla et al. [13] re-
ported the effect of ASCs on complex perianal fistulas. However, the majori-
ty of the treated fistulas had solely one track (62.5%), one external opening 
(75.0%) and pictured trans-sphincteric tracks (70.8). These characteristics of 
the fistula tracks do not match the AGA definition of complex perianal fistu-
las2. 
Detailed patient and study characteristics of included studies are displayed 
in Table A-1 and Table A-2. 
 
 
6.3 Results 
Patient safety 
C0008 – How safe are allogeneic mesenchymal stem cells  
in comparison to placebo? 
None of the included studies [11-13] reported cases of peri-interventional 
mortality neither in the MSC-group nor in the placebo group. 
Out of 204 patients, Panés et al. [11] reported 25 cases of anal abscesses. Out of 
those nine cases (MSC-group, n=103) and seven cases (control group, n=101) 
were reported as severe treatment-emerged adverse events, of which five cas-
es in each group were assessed as severe treatment-related adverse events. In 
comparison, in Molendijk et al. [12] four out of 21 patients developed anal 
abscesses, of which non were reported as severe. De la Portilla et al. [13] re-
ported four cases of anal abscesses out of 24 patients, with one case referred 
to as severe. 
Proctalgia (cramps in the anal area) was reported in 24 out of 204 patients in 
Panés et al. [11], of which one case in the control group (n=101) was assessed 
as severe. In comparison, in de la Portilla et al. [13] two out of 24 patients de-
veloped proctalgia, however, no case was rated as severe. 
Panés et al. [11] also reported one case of anal inflammation in the control 
group (n=101), which was reported as severe treatment-related adverse event. 
In de la Portilla et al. [13] two out of 24 patients developed anal inflamma-
tions, non of them were severe. 
                                                             
2 Defined as high fistulas involving more than two thirds of the external sphincter, of 
high inter-sphincteric, high trans-sphincteric, extra-sphincteric or supra-sphincteric 
origin and with possible multiple external openings. 
16/24 pts vollendeten  
24 Wochen, 
Durchschnittsalter:  
36 Jahre, 
CDAI-Score:  
≤200 zu Studienbeginn 
nicht alle berichteten 
Fisteln komplex gemäß 
der AGA Definition von 
komplexen, perianalen 
Fisteln 
keine Gesamt- oder 
krankheitsbedingten 
Mortalitätsfälle 
 
schwerwiegende anale 
Abszesse: 
1 RCT: 5 Fälle in  
MSC-Gruppe + 5 Fälle  
in Kontrollgruppe, 
einarmige Studie: 1 Fall 
schwerwiegende 
Proktalgia: 1 RCT:  
1 Fall in Kontrollgruppe 
schwerwiegende anale 
Entzündung: 1 RCT:  
1 Fall in Kontrollgruppe 
Safety 
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One severe case of liver abscess was reported in the control group (n=101) of 
Panés et al. [11]. In Molendijk et al. [12] one case of adenocarcinoma was 
reported in the first MSC-group (10 million cell dose).  
Pyrexia (fever) was reported in one out of five patients in the first MSC-
group (10 million cells dose) in Molendijk et al. [12], however, it was not se-
vere. In contrast, one pyrexia case out of four cases was assessed as severe in 
de la Portilla et al. (n=24) [13].  
By calculating the chance of developing a severe treatment-related adverse 
event, overall, out of 1,000 patients, 23 fewer patients of the MSC-group will 
develop a severe treatment-related adverse event compared to the control 
group, meaning that severe treatment-related adverse events occur more of-
ten in the control group (see Figure 6-1).  
All (severe) treatment-emerged and treatment-related adverse events are listed 
in more detail in Table A-1 and Table A-2 of the Appendix. 
 
Figure 6-1: Chance of developing severe treatment-related adverse event. 74 out of 1,000 patients, who do not receive 
MSC-therapy, will develop a severe adverse event, in comparison with 51 out of 1,000 patients, who do 
receive the intervention. In total, 23 fewer patients of the MSC-group will develop a severe treatment-
related adverse event compared to the placebo group; Reference: GRADEpro/GDT 
C0002 – Are the harms related to dosage or frequency of applying 
allogeneic mesenchymal stem cells? 
In the RCT of Molendijk et al. [12], three different doses were compared to 
one placebo group. In the first treatment group (MSC dose of 10 million cells, 
n=5) 17 adverse events occurred in five patients, whereas in the second treat-
ment group (MSC dose of 30 million cells, n=5), nine adverse events and in 
the third treatment group (MSC dose of 90 million cells, n=5) ten adverse 
events appeared in five patients. In comparison, 14 adverse events occurred 
in six patients of the control group (n=6). Thus, the lowest dose of MSCs re-
sulted, in more adverse events than the highest MSC-dose and, in more ad-
verse events than in the control group. Thereby, the authors pointed out that 
a lower dose of MSC is associated with increased adverse events. In fact, the 
middle dose of MSCs resulted in the lowest number of adverse events.  
 
schwerwiegendes 
Leberabszess: 1 RCT:  
1 Fall in Kontrollgruppe, 
Adenokarzinom: 1 RCT:  
1 Fall in MSC-Gruppe 1 
 
 
schwerwiegende Pyrexie: 
einarmige Studie: 1 Fall 
PatientInnen ohne  
MSC-Therapie höhere 
Chancen 
schwerwiegende, 
behandlungsbezogene, 
NW zu entwickeln 
häufigste unerwünschte 
NW in der MSC-Gruppe 
1, die wenigsten 
unerwünschten NW  
in der MSC-Gruppe 2 
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C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer this research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of allogeneic mesenchymal stem cells? 
No direct evidence was found to answer this research question.  
However, there are possible issues with MSC-therapies administered in pa-
tients with other comorbidities. As CD is an autoimmune disease, MSCs are 
aiming in suppressing the patient’s immune system. Therefore, patients might 
be more susceptible to other infections. 
C0007 – Are allogeneic mesenchymal stem cells associated  
with user-dependent harms? 
No direct evidence was found to answer this research question. However, the 
dosage of MSCs may have an impact on effectiveness and safety outcomes. 
Moreover, the way MSCs are injected may influence its effectiveness and 
safety. However, currently, no direct comparisons between different modali-
ties, i.e. intravenous vs. local injection, are available. 
 
 
 
 
 
keine Evidenz 
Effekt unklar bei 
PatientInnen mit 
Komorbiditäten 
MSC-Dosierung und 
Injektionsmethode 
möglichen Effekt auf 
Effektivität und 
Sicherheit 
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7 Quality of evidence 
The risk of bias (RoB) for individual studies was assessed with the Cochrane 
Collaboration’s tool for randomised trials [33] as well as with the Institute of 
Health Economics (IHE) checklist for single-arm studies [15]. Both assess-
ments are presented in Table A-3 and Table A-4 in the Appendix. One RCT 
[11] was rated with a moderate RoB, whereas the second RCT [12] was rated 
with a high RoB. In both RCTs, the blinding of the patients and the treating 
physician was unclear due to lacking information. Additionally, there is a RoB 
due to treatment effects of concomitant therapies in both RCTs and due to 
the small sample size in the RCT of Molendijk et al. [12]. The observational 
study [13] was rated with a high RoB. The most severe biases occurred due to 
the unclear study design and study population, the lack of information about 
co-interventions, as well as, the missing comparison of effects before and af-
ter the intervention. Furthermore, the conclusions were not supported by the 
results as the intervention was marked as safe, even though, two patients left 
the study because of severe adverse events. 
The strength of evidence was rated according to the GRADE scheme [16] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement, a third researcher was involved to solve 
the difference. A more detailed list of criteria applied can be found in the re-
commendations of the GRADE Working Group [16].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion; 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table Table 7-1 and in the evidence 
profile in Table A-5. 
Overall, the strength of evidence for the effectiveness of allogeneic MSCs in 
comparison to placebo was very low. The strength of evidence for the safety 
of allogeneic MSCs in comparison to placebo was low. For the comparison of 
the stem cells to fistula plugs or fibrin glue, no evidence is available.  
 
 
 
RoB für RCTs:  
Cochrane 
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1 RCT moderater RoB, 
1 RCT hoher RoB 
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Table 7-1: Summary of findings table of allogeneic mesenchymal stem cells 
Outcomes 
Anticipated absolute effects* (97.5% CI) Relative 
effect 
(97.5% CI) 
№ of 
participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments 
Risk with placebo Risk with allogeneic mesenchymal stem cells 
Quality of life (QoL) 
assessed with: IBDQ  
Panés (n=204): IG vs. CG: improvement +4.8 vs. +5.3 points; 
Molendijk (n=21): IG vs. CG: deterioration -0.1 (based on  
self-calculated mean of 3 IGs) +4.0 points 
 225 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW a,b,c 
Patient-reported 
outcome 
Quality of life (QoL) 
assessed with: SF-36  
Molendijk (n=21): IG vs. CG: deterioration -1.14 vs. improvement 
+0.8 points (self-calculated means across 8 health states) 
 21 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a,b,e,f 
Patient-reported 
outcome 
Quality of life (QoL) 
assessed with: PDAI 
Panés (n=204): IG vs. CG: improvement -2.3 vs -1.4 points; 
Molendijk (n=21): IG vs. CG: improvement -1.9 (based on  
self-calculated mean of 3 IGs) vs. -1.3 points 
 225 
(2 RCTs) 
⨁⨁⨁◯ 
MODERATE a,d 
Clinical assessment 
of severity of the 
disease 
Quality of life (QoL) 
assessed with: CDAI  
Panés (n=204): IG vs. CG: deterioration +4,7 vs. +0.8 points;  
Molendijk (n=21): IG vs. CG: improvement -8.0 (based on  
self-calculated mean of 3 IGs) vs. -17.8 points 
 225 
(2 RCTs) 
⨁⨁◯◯ 
LOW a,c,d 
Clinical assessment 
of severity of the 
disease 
Combined remission: 120 million 
adipose-tissue-derived MSCs assessed 
with: clinical and MRI assessment, 
follow up: mean 24 weeks  
The mean combined 
remission: 120 million 
adipose-tissue-derived 
MSCs was 0 % 
The mean combined remission: 120 million 
adipose-tissue-derived MSCs in the 
intervention group was 15 % more  
(0,2 more to 30,2 more) 
 212 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE e,g,h 
Significant 
difference, but wide 
confidence intervals 
Combined remission: different dosages 
bone-marrow-derived MSCs assessed 
with: clinical and MRI assessment, 
follow up: mean 12 weeks  
Molendijk (n=21): 
IG1 (10 million cells): 2/5 pts (40%), IG2 (30 million cells):  
4/5 pts (80%), IG3 (90 million cells): 1/5 pts (20%), CG: 2/6 pts (33.3%); 
significant difference IG2 vs. CG: p=0.06 
 21 
(1 RCT) 
⨁◯◯◯ 
VERY LOW a,c,f,i 
 
Response to 120 million adipose-tissue-
derived MSCs assessed with: closure of 
at least 50% of all treated external 
openings, follow up: mean 24 weeks  
The mean response  
to 120 million 
adipose-tissue-derived 
MSCs was 0 % 
The mean response to 120 million  
adipose-tissue-derived MSCs in the 
intervention group was 13 % more  
(0,1 fewer to 26,1 more) 
 212 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE e,g,h 
Wide confidence 
intervals, not 
statistically significant 
(p=0.054) 
Severe treatment-related adverse events 
(STRAE), follow up: mean 24 weeks  
74 per 1,000 51 per 1,000 RR 0.69 226 
(2 RCTs) 
⨁⨁◯◯ 
LOW a,f 
RR self-calculated 
 
* The risk in the intervention group (and its 97.5% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 97.5% CI). 
Abbreviations: CDAI = Crohn’s Disease Activity Index, CG = Control group, CI = Confidence interval, IBDQ = Irritable Bowel Disease Questionnaire, IG = Interventional group,  
PDAI = Perianal Disease Activity Index, pts = Patients, RCT = Randomised controlled trial, RR = Risk ratio, SF-36 = Short-form 36, STRAE = Severe treatment-related adverse event 
Explanations 
a Study with high risk of bias included  
b Subjective outcome measure  
c Heterogeneity of results  
d Clinical assessment  
e Not applicable (one study)  
f Small sample size  
g Study with moderate risk of bias  
h Wide confidence intervals  
i Differences in inclusion criteria (definition of complex fistula + CDAI score) 
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8 Discussion 
MSC-therapy presents a possible therapy method treating draining perianal 
fistulas with the aim of fistula closure. Currently, no product received market-
ing authorisation. However, marketing approval of Cx601 is expected by the 
manufacturer in February 2018. 
With regard to effectiveness of MSC-therapy, both RCTs reported a slight 
improvement in combined remission in the interventional group compared to 
the placebo group: Panés et al. [11] reported 50% (n=107) versus 34% of the 
patients (n=105) achieving combined remission after 24 weeks (mean differ-
ence 15.2%, CI 0.2-30.3, p=0.024). However, it remains questionable, why 
dichotomous outcomes were changed into percentages in order to calculate 
the mean difference. In Molendijk et al. [2] the highest percentage (80%) of 
the five patients of the second MSC-group achieving combined remission com-
pared to 33.3% of the six patients in the control group after 12 weeks (p= 
0.06). Response rates were only reported by Panés et al. [11]. Higher rates 
were reported in the MSC-group, however, this was not statistical significant 
(p=0.054). Based on the results of the QoL-assessment via different scores, 
MSCs were not deemed to improve QoL of the patients. Non of the two RCTs 
reported significance levels for the QoL-scores. 
Several sever adverse events were reported in the included studies with anal 
abscesses reported the most. Across all studies severe anal abscesses occurred 
more commonly in the MSC-groups than in the control groups. In contrast, 
severe cases of proctalgia, anal inflammation and liver abscesses were only 
reported in the control groups. De la Portilla et al. [13] reported one case of 
pyrexia out of 24 patients and in Molendijk et al. [12] one patient of the first 
MSC-group (10 million cell dose) developed an adenocarcinoma. Figure 6-1 
showed that the chance of developing severe treatment-related adverse events 
is higher for the placebo group than for the treatment group, thus, the devel-
opment of severe treatment-related adverse events, except immunity-related 
adverse events, such as common colds, might be triggered mostly by the in-
terventional process itself than by the effect of the MSC-treatment. However, 
this effect was based on low quality evidence. 
 
Interpretation of the findings 
Study quality, validity of endpoints and overall level of evidence 
The RCTs [11, 12] that investigated allogeneic MSCs compared to placebo 
had a moderate and high RoB, respectively, due to the unclear blinding of the 
patients and the treating physician as well as due to the possible treatment 
effects of concomitant therapies. The small sample size of one RCT [12] ad-
ditionally caused a high RoB. The RCTs reported inconclusive results for 
QoL across different scores, which could be partly explained by the subjec-
tiveness of reported QoL data by means of the IBDQ and SF-36, as well as, 
by the varying dosages across the RCTs. The overall level of evidence for the 
effectiveness endpoints was very low. 
MSC-Therapieziel: 
Schließung der Fisteln, 
bisher keine 
Marktzulassung 
Verbesserung in 
kombinierter Remission 
und Wirkung in der 
MSC-Gruppe, jedoch 
keine nachweißbare 
Verbesserung in 
Lebensqualität 
Sicherheit: anale 
Abszesse häufigste 
schwerwiegende NW,  
1 RCT: 1 Fall von 
Adenokarzinom 
moderates/hohes 
Verzerrungspotential, 
1 RCT kleine pts-Anzahl, 
Subjektivität QoL-Daten, 
Gesamtqualität der 
Evidenz für Effektivität 
sehr niedrig 
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The remaining observational study [13] had a high risk of bias due to the un-
clear study design and study population, the lack of information about co-
interventions, as well as due to the missing before-and-after comparison of 
the interventional effects. With regard to safety, the varying presentation of 
the adverse events across the three included studies, made it difficult to show, 
which adverse events are more likely to occur in which treatment group. In-
formation about the evaluation of the severity of adverse events was lacking. 
The overall level of evidence for the safety endpoints was low. 
 
Relevance of the outcomes assessed  
in clinical trials for patient-relevant benefits 
Effectiveness outcomes included in this review directly (QoL and severity of 
the disease) and indirectly (combined remission, response) measured the im-
pact on patients QoL. All outcomes were reported in a consistent way. How-
ever, QoL data via the IBDQ and SF-36 questionnaires involve a level of sub-
jectiveness, as data are assessed through questionnaires handed out to pa-
tients. Combined remission and response were reliable and valid tools in or-
der to indirectly measure changes in the severity of perianal fistulas, as both 
endpoints were investigated via clinical and/or MRI assessment. Possible im-
provements in remission rates but lacking improvement in QoL makes the 
findings/evidence inconclusive. 
 
Factors that may influence the external validity 
The three included studies were not consistent about the severity of disease 
of the participants at study start: The CDAI-scores, used as inclusion crite-
ria, ranged from ≤200 to ≤250. In addition, the definitions of complex peri-
anal fistulas varied across the studies. Both might indicate selective patient 
selection in the studies.  
Furthermore, different allogeneic stem cell types and stem cell dosages were 
used in the included studies. One study [12] showed that dosage differences 
can impact effectiveness and safety outcomes. However, there is no direct ev-
idence available whether cell type or dosage affect different stages of the dis-
ease and long-term results. 
In both RCTs [11, 12], placebo was used as the comparator. Based on clinical 
practice, fistula track filling material, such as fistula plugs, may be used as 
another comparator. Currently, no evidence is available that investigate al-
logeneic MSCs compared to treatments other than placebo.  
 
Evidence gaps, ongoing studies and related questions 
Currently, no long-term evidence of allogeneic MSCs beyond 24 weeks is 
available. Thus, it is currently questionable if there is a sustainable effect – 
long-term fistula closure – of the MSCs as well as if long-term severe treat-
ment-related adverse events are likely to occur after 24 weeks, which is cru-
cial to point out in the light of the worsening in the QoL-scores in Panés et 
al. from week 12 to week 24. In this regard, the concern of developing malig-
nancies after MSC-administration has to be emphasized. In Molendijk et al. 
[12], one case of adenocarcinoma occurred in the second interventional group, 
which presents, in fact, one out of five patients. The authors argued that this 
might be due to genetic reasons, as the father of this patient had died of same 
cancer at young age. However, the “not-correlation” between the occurrence 
fehlende Informationen 
zur Evaluation des 
Schweregrades der NW, 
Gesamtqualität der 
Evidenz für Sicherheit  
niedrig 
Subjektivität der Daten 
zur Lebensqualität, 
Messung von Remission 
und Reaktion 
vertrauenswürdig, 
jedoch insgesamt  
keine beweiskräftige 
Effektivität der MSCs 
mögliche 
PatientInnenselektion  
in den 3 Studien 
unterschiedliche 
Dosierungen und 
Zelltypen 
bisher Placebo einzige 
Vergleichstherapie 
keine Langzeitevidenz 
über 24 Wochen: 
Beunruhigung bezüglich 
Entwicklungen von 
Malignität 
Discussion 
LBI-HTA | 2018 47 
of the adenocarcinoma and the MSC-administration could not be proved. 
In fact, latest evidence reported that there can be unwarranted differentiation 
of the transplanted MSCs with the potential to suppress anti-tumour immune-
response and generate new blood vessels, which consequently can promote 
tumour growth and metastasis development [34, 35].  
Indeed, the effect of MSCs on the immune system is not sufficiently addressed 
in current evidence. As CD patients often already receive immune suppres-
sive treatments, an additional MSC-therapy may lead to patients being more 
receptive to infections. Therefore, further research is crucial, particularly, if 
the therapy leads to severe, life-threatening conditions for the patients after 
24 weeks. 
Several ongoing studies (Table A-7 and Table A-8) will provide further data 
on effectiveness and safety of MSCs compared to placebo. Two studies will 
provide long-term follow-up data for week 52 and week 104, respectively, and 
thus might fill the gap in the existing evidence. However, both studies are 
sponsored by the manufacturer TiGenix. The study (NCT01541579) assessing 
follow-up data until week 104 reported an expected study completion date of 
May 2017. However, by February 2018 the results are still pending. 
Moreover, the following questions still remain unanswered, thus, further re-
search is needed in these areas: 
 Direct comparisons of the different cell types, i.e. autologous versus al-
logeneic as well as adipose-tissue-derived versus bone-marrow-derived 
allogeneic MSCs [9, 19, 20]. 
 The optimal stem cell dose for allogeneic MSC-transplantation also 
with relation to stages of the disease remains unclear [9, 17]. 
 Optimal modalities (oral, intravenous, arteriovenous, local injection) 
for allogeneic MSC-administration [20]. A randomized controlled, 
phase III study (NCT00482092) will investigate the effect of intrave-
nous MSC-administration on draining fistulas (Table A-7). 
 Evidence if combinations of medical and surgical treatment approach-
es are superior to either single treatment alone [27]. 
 Direct comparisons of allogeneic MSC-therapy to other treatments 
than placebo, i.e. biologic therapy or alternative surgical treatment op-
tions, such as fibrin glue [10]. 
 Effectiveness and safety of allogeneic MSCs in rectovaginal fistulas in 
CD [9]. A small, single-arm, phase I study (NCT02677350) will also 
include CD patients with rectovaginal patients (Table A-8). 
 In female patients of child-bearing age with established CD, the cu-
mulative probability of developing perianal fistulas following delivery 
is lower as in the general CD population [27]. Nevertheless, evidence 
for effectiveness and safety of MSC-treatments in pregnant women is 
needed. 
  
zusätzliche MSC-
Therapie: PatientInnen 
möglicherweise 
empfänglicher für 
Infektionen 
fortlaufende Studien: 
2 RCTs mit  
Langzeitevidenz über  
24 Wochen 
weitere Forschung 
notwendig: 
direkter Vergleich der 
Zelltypen 
Evidenz für optimale 
Stammzelldosierung  
Evidenz für optimale 
Verabreichung der 
Stammzellen 
Evidenz für 
Therapiekombinationen 
direkte Vergleiche von 
MSC-Therapie zu z. B. 
chirurgischen Eingriffen 
Evidenz zu MSCs bei 
PatientInnen mit 
rektovaginalen Fisteln 
Evidenz zu MSCs bei 
schwangeren und/oder 
stillenden Frauen 
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Conclusion 
CD-associated complex perianal fistulas are associated with high recurrence 
rates. In combination with the productive age of the patients, the disease leads 
to additional societal costs. Therefore, MSC-therapy was suggested as an add-
on therapy in patients, refractory to current standard treatments.  
The current evidence of allogeneic MSC-therapy versus placebo includes two 
RCTs with a total number of 231 patients. Patients receiving MSCs are more 
likely to achieve combined remission, while inconclusive results of QoL of 
the patients, indicating no QoL improvements through MSC-therapies, were 
reported. No evidence is available comparing allogeneic MSC-therapy to oth-
er treatments than placebo.  
There are concerns about the lacking long-term outcomes beyond 24 weeks, 
especially for safety with regard to the correlation of allogeneic MSC-therapies 
and the development of malignancies [34, 35]. This concern is not sufficient-
ly addressed in existing clinical trials. 
The present systematic review focused solely on the effect of allogeneic MSCs 
on complex perianal fistulas caused by CD. In comparison, Cao et al. [18] 
reported the effect of MSCs on fistulising CD for both, autologous and al-
logeneic stem cells. Garcia-Olmo et al. [5] investigated the effect of autolo-
gous and allogeneic MSCs on perianal fistulas, including different treatment 
modalities. In Ye et al. [36] the efficacy and safety of autologous and alloge-
neic MSCs in refractory CD, without focusing on perianal disease, were in-
vestigated. In Grégoire et al. [20] the effect of autologous and allogeneic MSCs 
on irritable bowel diseases, not solely on CD, was reported. Overall, non of 
the present systematic reviews focused explicitly on complex perianal CD-
associated fistulas.  
Existing evidence concludes that QoL is not improved, while remission is. 
This is very inconclusive. Hence, based on this data, currently, one cannot 
recommend the intervention as an add-on treatment to existing treatment op-
tions for complex perianal fistulas caused by CD. 
 
 
MC gesellschaftliche 
Kosten, MSC als 
Zusatztherapie bei 
refraktären pts? 
bisherige Evidenz: 
2 RCTs (231 pts), 
größere Chance für 
kombinierte Remission, 
keine beweiskräftigen 
Lebensqualität-
verbesserungen 
 
keine Langzeitdaten 
über 24 Wochen, 
problematisch in Bezug 
auf Malignität 
 
im Vergleich zu 
vorhandenen Reviews: 
Fokus auf allogenen 
MSCs bei komplexen 
perianalen Fisteln 
insgesamt schwache 
Evidenz: MSCs zurzeit 
nicht als Zusatztherapie 
empfohlen 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according to choice is highlighted. 
Table 9-1: Evidence-based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
x The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that allogeneic MSCs in pa-
tients with complex perianal fistulas caused by CD who are refractory or in-
tolerant to standard medical therapy are … 
… more effective, because despite the slight improvement in combined 
remission, the data do not indicate improvement of QoL. Hence, the 
effectiveness of MSC-therapy in comparison to placebo remains un-
certain. 
… safer as placebo, because the occurrence of adverse events, except 
immunity-related adverse events, were similar in the treatment and the 
control group. Thus, MSC-therapy is meant to be as safe as, but not 
safer as the placebo-procedure. 
No evidence was available for comparing MSC-therapy to treatments other 
than placebo, i.e. fibrin glue or fistula plugs. 
New study results will potentially influence the effect and safety estimate con-
siderably. The re-evaluation is recommended in 2022 when further ongoing 
studies will be finished and thereby will bring additional evidence for long-
term effectiveness and safety beyond 24 weeks. 
 
unsichere Evidenz,  
dass MSCs effektiver 
und sicherer sind als 
Placebo-Therapien 
Placebo bisher  
einziger untersuchter 
Komparator 
 
Re-evaluation für  
2022 empfohlen 
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Appendix 
Evidence tables of individual studies included  
for clinical effectiveness and safety 
Table A-1: Allogeneic expanded mesenchymal stem cells: Results from randomised controlled trials 
Author, year Panés et al., 2016 [11] Molendijk et al., 2015 [12] 
Country Spain, Belgium, Austria, Canada, 
Germany, France, Italy, Israel 
The Netherlands 
Sponsor TiGenix DigestScience Foundation 
Intervention/Product Allogeneic expanded adipose-derived 
MSCs (Davardstrocel, Cx601) 
IG: 120 million cells for a maximum of  
3 fistulas (n=107) 
Allogeneic expanded bone-marrow-derived MSCs 
IG1: 1 x 107 (10 million cells) (n=5) 
IG2: 3 x 107 (30 million cells) ( (n=5) 
IG3: 9 x 107 (90 million cells) (n=5) 
Comparator Placebo, namely 24 mL saline solution 
(n=105) 
Placebo, namely 0.9% NaCI/5% human albumin 
solution with no cells (n=6) 
Study design Randomised, double-blind, parallel-
group, placebo-controlled study 
(NCT01541579) 
Randomised, double-blind,  
placebo-controlled study 
(NCT01144962) 
Number of patients 2123 21 
Inclusion criteria  ≥18 years of age 
 CDAI score of ≤220: non-active  
or mildly active luminal disease 
 Complex perianal fistulas 
 Refractory to at least one of the 
treatments: antibiotics ciprofloxacin 
or metronidazole, 
immunomodulators azathioprine,  
6-mercaptopurine, or methotrexate 
or induction or maintenance of  
anti-TNF agents 
 ≥18 years of age 
 CDAI score of <250 at screening and baseline 
 Actively draining perianal fistulas 
 Refractory to conventional therapies, namely 
anti-TNF agents, antibiotics, steroids, thiopurines, 
methotrexate, surgery or a combination thereof 
 1-2 internal openings and 1-3 fistula tracts 
 Diagnosis of CD at least 3 months before enrollment 
 Stable dose of current drugs (mesalamine and 
steroids ≥4 weeks; immunosuppressive drugs  
≥8 weeks; anti-TNF agents ≥8 weeks) 
Exclusion criteria  Rectovaginal fistulas 
 Active severe proctitis 
 Rectal or anal stenosis 
 Abscess 
 Previous fistula surgery other than 
drainage or seton placement 
 Diverting stomas 
 Collections >2 cm if not properly 
drained during preparation visit 
 No previous treatment for perianal 
fistulizing CD, including antibiotics 
 Treatment with corticosteroids 
within 4 weeks before study start 
 Rectovaginal fistulas 
 Active luminal disease 
 Anal or rectal stricture 
 Acute perianal infection 
 Need for immediate surgery 
 Complex perianal fistulas with >2 internal openings 
 Opportunistic infection within 6 months before 
screening or serious infection in previous 3 months 
 Infection and need for antibiotic treatment 
 Use of antibiotics after trial inclusion 
 Use of any investigational drug within 1 month 
before screening or within 5 half-lives of the 
investigational agent 
 Change in concomitant medication 
 Not able or willing to undergo MRI 
 Renal or hepatic failure 
 Documented human immunodeficiency virus 
infection, active hepatitis B, C, or tuberculosis 
 Malignancy within past 5 years 
 History of lymphoproliferative disease 
 Pregnancy, breastfeeding or  
no adequate contraception 
                                                             
3 The number of patients was not clearly defined. In clinicaltrials.gov the number of patients included was 278.  
In the study 289 patients were assessed for eligibility and 212 patients were randomly assigned. 
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Author, year Panés et al., 2016 [11] Molendijk et al., 2015 [12] 
The mean age of 
patients (years): 
IG: 39.0; CG: 37.60 IG1: 40.4; IG2: 40.8; IG3: 33.4;  
CG: 37.3 
Follow-up (weeks)4 After intervention: 
 12 weeks 
 24 weeks 
After intervention: 
 12 weeks 
 24 weeks 
Loss to follow-up, n (%) IG: 19 (17.8); CG: 22 (21) 0 (0) 
Outcomes 
Efficacy 
QoL: 
(1) (s)IBDQ 
(high is better) 
(2) SF-36 
(high is better) 
(3) PDAI 
(low is better) 
(4) CDAI 
(lower is better) 
(1) IBDQ scores (week 0 to 24)5: 
Total: 
IG: 173.5 to 178.3; CG: 169.4 to 174.7 
Bowel function: 
IG: 57.1 to 57.2; CG: 56.8 to 56.4 
Emotional status: 
IG: 63.2 to 64.7; CG: 61.5 to 63.9 
Systemic symptoms: 
IG: 25.9 to 26.2; CG: 25.0 to 25.6 
Social function: 
IG: 27.7 to 29.5; CG: 26.5 to 28.4 
(2) SF-36 scores: NA 
(3) PDAI scores: 
Week 0 to 12: 
IG: 6.7 to 3.9; CG: 6.5 to 4.9 
Week 0 to 24: 
IG: 6.7 to 4.4; CG: 6.5 to 5.1 
(4) CDAI scores (week 0 to 24): 
Total: 
IG: 87.8 to 92.5; CG: 93.3 to 94.1 
Number of liquid stools: 
IG: 9.8 to 9.5; CG: 9.3 to 10.0 
Abdominal pain: 
IG: 1.6 to 2.7; CG: 2.0 to 3.0 
General well being: 
IG: 2.7 to 3.1; CG: 3.2 to 3.3 
(1) sIBDQ scores (week 0 to 24): 
IG1: 61.0 to 60.0; IG2: 48.8 to 51.7;  
IG3: 52.8 to 50.5; CG: 55.3 to 59.3 
(2) SF-36 scores (week 0 to 24): 
Physical functioning: 
IG1: 96.0 to 97.0; IG2: 75.0 to 87.5;  
IG3: 92.0 to 92.0; CG: 85.o to 86.7 
Physical role functioning: 
IG1: 80.0 to 73.8; IG2: 53.8 to 51.6;  
IG3: 75.0 to 71.3; CG: 69.8 to 70.8 
Bodily pain: 
IG1: 91.6 to 81.3; ; IG2: 71.6 to 67.5;  
IG3: 74.6 to 77.8; CG: 62.2 to 74.2 
General health perceptions: 
IG1: 68.0 to 61.6; IG2: 33.4 to 30.5;  
IG3: 64.6 to 60.2; CG: 58.2 to 51.8 
Vitality: 
IG1: 73.8 to 70.0; IG2: 38.8 to 39.1;  
IG3: 62.5 to 50.0; CG: 64.0 to 63.5 
Social functioning: 
IG1: 90.0 to 82.5; IG2: 57.5 to 62.5;  
IG3: 77.5 to 80.0; CG: 87.5 to 87.5 
Emotional role functioning: 
IG1: 85.0 to 80.0; IG2: 51.7 to 62.5;  
IG3: 68.3 to 71.7; CG: 80.6 to 79.2 
Mental health: 
IG1: 81.0 to 85.0; IG2: 51.0 to 53.8;  
IG3: 70.0 to 66.0; CG: 79.2 to 80.0 
(3) PDAI scores (estimation based on graphical 
representation6): 
week 0 to 12: 
IG1: 4.4 to 3.2; IG2: 3.8 to 1.0;  
IG3: 5.0 to 3.9; CG: 5.2 to 5.3 
Week 0 to 24: 
IG1: 4.4 to 1.8; IG2: 3.8 to 1.5 (significant, p=0.03); 
IG3: 5.0 to 4.3; CG: 5.2 to 3.9 
(4) CDAI scores (week 0 to 24): 
IG1: 80.2 to 64.8; IG2: 203.3 to 171.3;  
IG3: 57.3 to 80.8; CG: 75.8 to 58.0 
Fistula relapse-free 
survival 
NA NA 
                                                             
4 In week 12 efficacy data were assessed. In week 24 both, efficacy and safety data were assessed. 
5 All QoL scores in Panés et al. were reported for the modified intention-to-treat population (204 pts not the total 
intention-to-treat population of 212). 
6 Figure 3 of Molendijk et al. [2]. 
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Author, year Panés et al., 2016 [11] Molendijk et al., 2015 [12] 
Combined remission,  
n (%) 
Week 247: 
IG: 53 (50); CG: 36 (34) 
(significant difference 15.2%,  
97.5% CI 0.2-30.3; p=0.024) 
Week 128: 
IG1: 2 (40); IG2: 4 (80); IG3: 1 (20); CG: 2 (33.3) 
(significant difference IG2 vs. CG: p=0.06) 
Response, n (%) Week 249: 
IG: 71 (66); CG: 56 (53) 
(difference 13.0%, 97.5%  
CI -0.1-26.1; p=0.054) 
NA 
Safety 
TEAE, n (%) Total number of adverse events  
per treatment group10: 
IG: 49 (48); CG: 44 (43) 
Anal abscess:  
IG: 12 (12); CG: 13 (13) 
Diarrhoea: 
IG: 7 (7); CG: 3 (3) 
Abdominal pain: 
IG: 4 (4); CG: 6 (6) 
Proctalgia (cramps in the anal region): 
IG: 13 (13); CG: 11 (11) 
Nasopharyngitis (common cold): 
IG: 10 (10); CG: 5 (5) 
Fistula: 
IG: 3 (3); CG: 6 (6) 
Total number of adverse events  
per treatment group11: 
IG1: 17 (340); IG2: 9 (180); IG3: 10 (200); CG: 14 (233) 
Anal abscess: 
IG1: 1 (20); IG2: 1 (20); IG3: 1 (20); CG: 1 (16.7) 
Diarrhea: 
IG1: 1 (20); CG: 1 (16.7) 
Abdominal pain: IG1: 1 (20); IG2: 1 (20); IG3: 3 (60) 
Painful perianal swelling: IG1: 1 (20); CG: 3 (50) 
Not painful perianal swelling: IG1: 1 (20); CG: 1 (16.7) 
Nasopharyngitis (common cold): 
IG1: 5 (100); IG2: 2 (40); IG3: 1 (20); CG: 2 (33.3) 
Pyrexia (fever (29.7°C)): IG2: 1 (20) 
Blood from fistula: IG1: 1 (20) 
Painful anal sphincters: 
 Fissura ani: IG1: 1 (20) 
 Anal blood: CG: 1 (16.7) 
 Anal pus: IG2: 1 (20) 
 Thrombosed haemorrhoid: CG: 1 (16.7) 
 Pimples buttocks: IG3: 1 (20); CG: 1 (16.7) 
 Pimples abdomen: CG: 1 (16.7) 
 Mild activity CD: IG1: 1 (20); CG: 1 (16.7) 
 Exacerbated activity CD: IG1: 1 (20) 
 Flatulence: CG: 1 (16.7) 
 Nausea: IG3: 1 (20) 
 Vomiting: IG3: 1 (20) 
 Lack of appetite: IG1: 1 (20) 
 Pneumonia: IG2: 1 (20) 
 Otitis: IG2: 1 (20) 
 Headache: IG2: 2 (40) 
 Back pain: IG3: 1 (20) 
 Rosacea: IG1: 1 (20) 
 Cold sore: IG1: 1 (20) 
Postoperative anal pain and pus and/or bloody 
discharge from the fistula or anus: 21 (100) 
                                                             
  7 n presents the number of patients who achieved closure of all treated external openings and had an absence of 
collections ≥2 cm; Percentages present the proportion of patients with combined remission of the total number of 
patients per treatment group. 
  8 MRI assessment was done only at week 12, thus, combined remission could only be measured in accordance with 
the definition with 12 weeks of follow-up; n presents the number of all individual fistulas demonstrate the ab-
sence of discharge and of collections ≥2 cm; percentages present the proportion of completely healed fistulas of 
the total number of all individual fistulas. 
  9 n presents the number of patients who achieved closure of at least 50% of all treated external openings; percent-
ages present the proportion of patients with a respond of the total patients per treatment group. 
10 Presented are TEAEs that have occurred in ≥5% of patients of all treatment groups up to 24 weeks of follow-up. 
11 If a treatment group is not mentioned for a specific AE, this AE did not occur in any patient of that treatment group. 
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Author, year Panés et al., 2016 [11] Molendijk et al., 2015 [12] 
TRAE, n (%) Anal abscess12: IG: 6 (6); CG: 9 (9) 
Proctalgia (cramps in the anal region): 
IG: 5 (5); CG 9 (9) 
Procedural pain: IG: 1 (1); CG: 2 (2)  
Fistula discharge: IG: 1 (1); CG: 2 (2) 
Induration: IG: 0; CG: 2 (2) 
NA 
STEAE, n (%) Anal abscess: IG: 9 (9); CG: 7 (7) NA 
STRAE, n (%) Anal abscess13: IG: 5 (5); CG: 5 (5) 
Proctalgia (cramps in the anal region): 
IG: 0; CG: 1 (1) 
Anal inflammation: IG: 0; CG: 1 (1) 
Liver abscess: IG: 0; CG: 1 (1) 
Adenocarcinoma14: IG1: 1 (20) 
Abbreviations: CD = Crohn’s disease, CDAI = Crohn’s Disease Activity Index, TNF = tumour necrosis factor,  
IG = interventional group, CG = control group, PDAI = Perianal Disease Activity Index, CI = confidence interval,  
SD = standard deviation, (s)IBDQ = (short-form) Irritable Bowel Disease Questionnaire, NA = not available, p = p-value, 
pts = patients, QoL = quality of life, TEAE = treatment-emerged adverse event, TRAE = treatment-related adverse event, 
STEAE = severe treatment-emerged adverse event, STRAE = severe treatment-related adverse event, n = number,  
MSC = mesenchymal stem cells 
 
Table A-2: Allogeneic expanded mesenchymal stem cells: Results from an observational study 
Author, year de la Portilla et al., 2013 [13] 
Country Spain 
Sponsor TiGenix 
Intervention/Product Allogeneic expanded adipose-derived MSCs: 
20 million cells/draining fistula tract 
additional 40 million cells/draining fistula tract if fistula closer was incomplete  
at week 12 
Comparator None 
Study design Prospective interventional single-arm study (NCT01372969) 
Number of pts 24 
Inclusion criteria  ≥18 years of age 
 CDAI score ≤200: non-active luminal CD 
 Diagnosis of CD at least 12 months before enrolment 
 Presence of persistent and active complex perianal fistula with <3 fistulous tracts 
and/or external openings 
 Good general state of health 
Exclusion criteria  Rectovaginal, anal, or non-perianal enterocutaneous fistulas 
 Any abscess before start of treatment 
 Presence of setons unless removed prior to treatment 
 Rectal and/or anal stenosis 
 Severe proctitis or dominant active luminal disease requiring immediate therapy 
 Treatment with anti-TNF agent in previous 8 weeks or tacrolimus or  
cyclosporine in previous 4 weeks 
 Congenital or acquired immunodeficiency and allergy to anaesthetics or  
MRI contrast 
Age of patients (yrs) 36.0 
                                                             
12 Presented are TRAEs and STEAEs that have occurred in ≥2% of patients of all treatment groups up to 24 weeks 
of follow-up. 
13 All STRAEs are reported that occurred up to week 24 of follow-up. 
14 One patient treated with 10 million MSCs developed an adenocarcinoma of the cecum with peritoneal  
carcinomatosis. The correlation between the intervention and the occurrence of an adenocarcinoma was unclear. 
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Author, year de la Portilla et al., 2013 [13] 
Follow-up (weeks) After intervention: 
 12 weeks 
 24 weeks 
Loss to follow-up, n (%) 815 
Outcomes 
Efficacy (n=22) 
QoL: 
(1) (s)IBDQ 
(high is better) 
(2) SF-36 
(high is better) 
(3) PDAI 
(low is better) 
(4) CDAI 
(lower is better) 
(1) (s)IBDQ: NA 
(2) SF-36 scores: NA 
(3) PDAI scores (estimations16): 
Week 0: 6.2; Week 12: 5.2; Week 24: 3.9 
(significantly decreased at week 24 of more than 37% compared to baseline mean value; 
p=0.0076) 
(4) CDAI scores (estimations): 
Week 0: 80; Week 12:91; Week 24:80 
Fistula-relapse free survival NA 
Combined remission17, n (%) Week 12: 6 (30) of 24 of 20 patients 
Week 24: NA 
Response, n (%) NA 
Safety (n=24) 
TEAE, n (%)18  Proctalgia (cramps in the anal region): 2 (8.3) 
 Pyrexia (fever): 4 (16.7) 
 Anal abscess: 4 (16.7) 
 Anal fistula infection: 2 (8.3) 
 Increase in C reactive protein: 3 (12.5) 
 Musculoskeletal and connective tissue disorders: 3 (12.5) 
 Anxiety: 3 (12.5) 
TRAE, n (%)  Anal abscess: 3 (12.5) 
 Pyrexia (fever): 1 (4.2) 
 Uerine leiomyoma: 1 (4.2) 
STEAE, n (%) NA 
STRAE, n (%)  Pyrexia (fever): 1 (4.2) 
 Perianal abscess: 1 (4.2) 
Abbreviations: CD = Crohn’s disease, CDAI = Crohn’s Disease Activity Index, TNF = Tumour necrosis factor,  
MRI = Magnetic Resonance Imaging, MSS = Magnetic Resonance Imaging Score of Severity, p = p-value, pts = patients, 
TEAE = treatment-emerged adverse event, TRAE = treatment-related adverse event, STEAE = severe treatment-emerged 
adverse event, STRAE = severe treatment-related adverse event, PDAI = Perianal Disease Activity Index, NA = not available, 
MSC = mesenchymal stem cells 
 
 
                                                             
15 Of 24 treated patients, 16 patients completed the study period and 8 were prematurely withdrawn for various rea-
sons: 2 dropped out due to protocol deviations (1 patient received antibiotic treatment for more than 4 weeks; 
1 patient did not perform the screening pregnancy test at screening or visit). Other premature withdrawal reasons 
were presence of adverse event (perianal abscess) in 2 patients and outbreak of the underlying Crohn’s disease in 
4 cases. 
16 Data of PDAI- and CDAI-scores were estimated from Figure 2 of de la Portilla et al. [3]. 
17 Combined remission was defined as the fistula closure assessed via clinical and MRI assessment. 
18 Presented are TEAEs and TRAEs that have been occurred in >1 patient of the full analysis population  
(24 patients). 
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Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[37] and in the Guideline of EUnetHTA [14]. 
Table A-3: Risk of bias – study level (randomised studies), see [33] 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
ADMIRE I, [11] yes yes unclear19 unclear20 yes no21 moderate 
NCT01144962, [12] unclear22 unclear23 unclear24 Unclear25 no25 no26 high 
 
 
 
                                                             
19 No information about the blinding of the patients was reported. 
20 The surgeon was unmasked, while the clinicians assessing the efficacy were blinded. 
21 Possible bias due to treatment effects of concomitant therapies. 
22 No information about the adequate generation of the randomisation was reported. 
23 No information about the adequate allocation concealment was given. 
24 No information about the blinding was reported. 
25 No serious adverse events have been reported. 
26 Possible bias due to small sample size and treatment effects of concomitant therapies. 
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Table A-4: Risk of bias – study level (case series), see [3] 
Study reference/ID 
De la Portilla, 
2013, [13] 
Study objective 
1. Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction,  
or methods section? 
yes 
Study design 
2. Was the study conducted prospectively? unclear 
3. Were the cases collected in more than one centre? yes 
4. Were participants recruited consecutively? unclear 
Study population 
5. Were the characteristics of the participants included in the study described? partial27 
6. Were the eligibility criteria (inclusion and exclusion criteria) for entry into the study clearly stated? yes 
7. Did participants enter the study at a similar point in the disease? unclear 
Intervention and co-intervention 
8. Was the intervention clearly described in the study? yes 
9. Were additional interventions (co-interventions) clearly described? partial28 
Outcome measures 
10. Were relevant outcome measures established a priori? yes 
11. Were outcome assessors blinded to the intervention that patients received? yes 
12. Were the relevant outcomes appropriate objective/subjective methods? n0 
13. Were the relevant outcome measures made before and after the intervention? no29 
Statistical analysis 
14. Were the statistical tests used to assess the relevant outcomes appropriate? yes 
Results and conclusions 
15. Was follow-up long enough for important events and outcomes to occur? yes 
16. Were losses to follow-up reported? no 
17. Did the study provide estimates of random variability in the data analysis of relevant outcomes? partial 
18. Were the adverse events reported? yes 
19. Were the conclusions of the study supported by the results? no30 
Competing interests and sources of support 
20. Were both competing interest and source of support for the study reported? yes 
Overall Risk of bias high 
 
 
                                                             
27 Not all relevant patient characteristics were reported. 
28 It can be assumed that there might be concomitant therapies like in other bigger studies. 
29 Outcome measures were made 12 and 24 weeks after the interventional process. 
30 The intervention was reported as safe, even if two patients left the study, due two severe adverse events  
(i.e. anal abscess and pyrexia). 
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Table A-5: Evidence profile: efficacy and safety of allogeneic mesenchymal stem cells in Crohn’s disease patients with complex perianal fistulas [4] 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Allogeneic 
mesenchymal 
stem cells Placebo 
Relative 
(97.5% CI) 
Absolute 
(97.5% CI) 
Quality of life (assessed with: IBDQ) 
2  randomised 
trials  
very 
serious a,b 
serious c not serious  not serious  none  Panés (n=204): IG vs. CG: improvement + 4.8 vs. + 5.3 points;  
Molendijk (n=21): IG vs. CG: deterioration -0.1 (based on  
self-calculated mean of 3 IGs) + 4.0 points 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Quality of life (assessed with: PDAI) 
2  randomised 
trials  
serious a,d not serious  not serious  not serious  none  Panés (n=204): IG vs. CG: improvement -2.3 vs -1.4 points; 
Molendijk (n=21): IG vs. CG: improvement -1.9 (based on  
self-calculated mean of 3 IGs) vs. -1.3 points 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Quality of life (assessed with: CDAI) 
2  randomise
d trials  
serious a,d serious c not serious  not serious  none  Panés (n=204): IG vs. CG: deterioration + 4,7 vs. +0.8 points;  
Molendijk (n=21): IG vs. CG: improvement -8.0 (based on  
self-calculated mean of 3 IGs) vs. -17.8 points 
⨁⨁◯◯ 
LOW 
CRITICAL 
Quality of life (assessed with: SF-36) 
1  randomised 
trials  
very 
serious a,b 
not serious e not serious  serious f none  Molendijk (n=21): IG vs. CG: deterioration -1.14 vs. improvement 
+0.8 points (self-calculated means across 8 health states) 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Combined remission: 120 million adipose-tissue-derived MSCs (follow up: mean 24 weeks; assessed with: clinical and MRI assessment) 
1  randomised 
trials  
not 
serious g 
not serious e not serious  serious h none  107 105 - mean 15% more  
(0.2 more to 30.2 more) 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Combined remission: different dosages bone-marrow-derived MSCs (follow up: mean 12 weeks; assessed with: clinical and MRI assessment) 
1  randomised 
trials  
serious a serious c serious i serious f none  Molendijk (n=21): IG1 (10 million cells): 2/5 pts (40%), IG2 (30 
million cells): 4/5 pts (80%), IG3 (90 million cells): 1/5 pts (20%), 
CG: 2/6 pts (33.3%); significant difference IG2 vs. CG: p=0.06 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Response to 120 million adipose-tissue-derived MSCs (follow up: mean 24 weeks; assessed with: closure of at least 50% of all treated external openings) 
1  randomised 
trials  
not 
serious g 
not serious e not serious  serious h none  107 105 - mean 13% more  
(0.1 fewer to 26.1 more) 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Severe treatment-related adverse events (follow up: mean 24 weeks) 
2  randomised 
trials  
serious a not serious  not serious  serious f none  6/118  
(5.1%) 
8/108 
(7.4%) 
RR 0.69 23 fewer  
per 1,000 
⨁⨁◯◯ 
LOW 
CRITICAL 
Abbreviations: CDAI = Crohn’s Disease Activity Index, CG = Control group, CI = Confidence interval, IBDQ = Irritable Bowel Disease Questionnaire, IG = Interventional group, N = Number, 
PDAI = Perianal Disease Activity Index, pts = Patients, RCT = Randomised controlled trial, RR = Risk ratio, SF-36 = Short-form 36, STRAE = Severe treatment-related adverse event 
Explanations 
a Study with high risk of bias included  
b Subjective outcome measure  
c Heterogeneity of results  
d Clinical assessment  
e Not applicable (one study)  
f Small sample size  
g Study with moderate risk of bias  
h Wide confidence intervals  
i Differences in inclusion criteria  
(definition of complex fistula + CDAI score) 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
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Applicability table 
Table A-6: Summary table characterizing the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The study population of the included studies differed with regard to the CDAI score. In the three studies, 
the CDAI scores for inclusion in the study ranged from ≤200 to ≤250, indicating different severity of 
the disease at study start. In addition, the definition of complex perianal fistulas differed from the 
definition of the American Gastroenterological Association in two studies. Thus, the complexity of 
the fistula tracks might not be the same for every study, even though the studies explicitly stated that 
they include patients with complex perianal fistulas. The mean age of participants was consistent 
across the studies (range: 37-41 years) and was reflective for the usual time of diagnosing perianal 
fistulas. All studies delivered evidence from European populations. 
Intervention The interventions differed in allogeneic stem cell type and dosage. Two studies administered 
adipose-derived mesenchymal stem cells, while the third study assessed bone-marrow-derived stem 
cells. Currently, there are no direct comparisons of these two cell types. The dosages of the studies 
ranged from 10 million to 120 million cells (for a maximum of three fistula tracks). In one study the 
second dose of cells was administered in case of lacking response to the first dose. Based on the dose-
escalating study [12], a higher dosage is not necessarily associated with better effects on patients 
outcomes. However, further research is needed for the long-term follow-up (>24 weeks). 
Comparators In both RCTs, placebo was used as the comparator. In one study, placebo was defined as saline solution, 
while in the second RCT, it was defined as human albumin solution. There are suggestions that fistula 
track filling material, such as fistula plug could be used as a comparator treatment. However, there  
is no evidence of MSC-therapy compared to other treatments than placebo. 
Outcomes Not all critical efficacy endpoints were reported by all included studies. With regard to combined 
remission, Panés et al. reported it for 24 weeks, while the other two studies assessed it for 12 weeks. 
Furthermore, response to treatment was only reported by Panés et al. There were difference in the 
reported safety outcomes, and measurements were not clearly described. Severe treatment-related 
adverse events were only assessed in two studies. 
Setting One RCT was conducted in various hospitals in Spain, Belgium, Austria, Germany, France, Italy, Canada, 
and Israel. The other RCT was conducted at the Leiden University Medical Center in the Netherlands. 
The single-arm study was conducted in the Virgen del Rocio University Hospital in Spain. Two out of 
the three studies were sponsored by the manufacturer TiGenix. The Dutch study was funded by the 
DigestScience Foundation, which is also sponsored by one manufacturer (Takeda). 
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List of ongoing randomised controlled trials 
Table A-7: List of ongoing randomised controlled trials of adult human allogeneic mesenchymal stem cells 
Identifier/Trial name 
Patient 
population 
Estimated 
enrolement Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT03279081 
Adult phase-III randomized, double-blind, 
parallel-group, placebo-controlled, 
multicentre study to assess efficacy and 
safety of Cx601, allogeneic expanded 
adipose-derived stem cells for complex 
perianal fistula(s) in Crohn’s disease. 
ADMIRE-CD-II 
Complex 
perianal 
fistula(s) 
associated 
with Crohn’s 
disease 
326 Adult allogeneic expanded 
adipose-derived stem cells 
(eASC), Cx601 
Placebo Combined Remission of 
complex perianal fistula(s) at 
week 24 
October 1, 2021 TiGenix S.A.U. 
NCT01541579 
A phase III, randomized, double-blind, 
parallel group, placebo-controlled, 
multicentre study to assess efficacy and 
safety of eASCs for the treatment of 
perianal fistulising Crohn’s disease over 
a period of 24 weeks and an extended 
follow-up period up to 104 weeks. 
Complex 
anal fistulas 
associated 
with Crohn’s 
disease 
278 Allogeneic eASCs 5 million 
cells/mL, Cx601 
Placebo Combine remission of perianal 
fistulising Crohn’s: clinical 
assessment of closure of all 
treated external openings that 
were draining at baseline despite 
gentle finger compression at 
week 24, and absence of 
collections > 2 cm of the 
treated perianal fistulas 
confirmed by centrally blinded 
MRI assessment by week 24 
May 2017 TiGenix S.A.U. 
NCT00482092 
A phase III, multicenter, placebo-
controlled, randomized, double-blind 
study to evaluate the safety and efficacy 
of PROCHYMAL® (ex vivo cultured 
adult human mesenchymal stem cells) 
intravenous infusion for the induction 
of remission in subjects experiencing 
treatment-refractory moderate-to-severe 
Crohn’s disease 
Treatment-
resistant 
Moderate- 
to-severe 
Crohn’s 
Disease 
330 PROCHYMAL® adult human 
mesenchymal stem cells 
Intravenous infusion of 
suspension of adult human 
mesenchymal stem cells,  
a total of 1200 million  
(high dose) or 600 million 
(low dose) cells infused in 
four visits over two weeks. 
Placebo Disease remission  
(CDAI at or below 150)  
[ Time Frame: 28 days ] 
Reduction in number of 
draining fistulas  
[ Time Frame: 28 days ] 
July 2018 Mesoblast 
International 
Sàrl 
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Table A-8: List of ongoing observational trials of adult human allogeneic mesenchymal stem cells 
Identifier/Trial name 
Patient 
population 
Estimated 
enrolement Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT02677350 
A phase I, pilot trial to evaluate the safety 
and efficacy of injection of allogeneic 
mesenchymal bone-marrow-derived 
human stem cells in patients with 
fistulising Crohn’s disease. 
GALENE 
Complex or 
multiple 
perianal or 
rectovaginal 
fistulas 
20 Allogeneic bone  
marrow-derived human 
mesenchymal stem cells 
(hMSCs), 2 x 10^7 hMSCs  
at week 4 intervals for a 
maximum of 4 treatment 
sessions 
None Until 16 months: treatment-
emergent adverse event rates, 
infections, hospitalizations or 
surgical intervention; physical 
examination; vital signs; 
laboratory tests (biochemistry, 
haematology, urinalysis) 
March 2025 Joshua M 
Hare, 
University  
of Miami 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Mesenchymal Stem Cells for Crohn’s Fistula 
Search Date:13.12.2017 
ID Search 
#1 MeSH descriptor: [Rectal Fistula] explode all trees 
#2 (anal or anus or ano* or peri*an* or rect*) near fistul* (Word variations have been searched) 
#3 MeSH descriptor: [Crohn Disease] explode all trees 
#4 Crohn* (Word variations have been searched) 
#5 Crohn* near fistula* (Word variations have been searched) 
#6 #1 or #2 or #3 or #4 or #5 
#7 MeSH descriptor: [Mesenchymal Stromal Cells] explode all trees 
#8 MeSH descriptor: [Mesenchymal Stem Cell Transplantation] explode all trees 
#9 (mesenchymal or stroma*) near cell* (Word variations have been searched 
#10 MSC:ti,ab,kw 
#11 #7 or #8 or #9 or #10 
#12 #6 and #11 
#13 stem cell* near ((anal or anus or ano* or peri?an* or rect*) near (fistul* or Crohn*)) (Word variations have 
been searched) 
#14 Alofisel (Word variations have been searched) 
#15 TiGenix (Word variations have been searched) 
#16 "Living Medicines" (Word variations have been searched) 
#17 Cx*601 (Word variations have been searched) 
#18 #12 or #13 or #14 or #15 or #16 or #17 
Total: 18 Hits 
 
 
Search strategy for CRD 
Search Name: Stem Cell Therapy for Crohns Fistula 
Search Date:13.12.2017 
ID Search 
#1 MeSH DESCRIPTOR Rectal Fistula EXPLODE ALL TREES 
#2 ((anal OR anus OR ano* OR peri*an* OR rect*) NEAR fistul*) 
#3 MeSH DESCRIPTOR Crohn Disease EXPLODE ALL TREES 
#4 (Crohn*) 
#5 (Crohn* NEAR Fistul*) 
#6 #1 OR #2 OR #3 OR #4 OR #5 
#7 MeSH DESCRIPTOR Mesenchymal Stromal Cells EXPLODE ALL TREES 
#8 MeSH DESCRIPTOR Mesenchymal Stem Cell Transplantation EXPLODE ALL TREES 
#9 ((mesenchymal OR stroma*) NEAR cell*) 
#10 #7 OR #8 OR #9 
#11 #6 AND #10 
#12 (stem cell* NEAR (fistul* OR Crohn*)) 
#13 (Alofisel) 
#14 (cx601) 
#15 (cx-601) 
#16 (TiGenix) 
#17 (Living Medicines) 
#18 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 
Total: 18 Hits 
Appendix 
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Search strategy for Embase 
Search Date:13.12.2017 
No. Query Results Results 
#18 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 524 
#17 ‘living medicines’ 4 
#16 tigenix:df,dn,mn,tn 35 
#15 ‘cx 601’ 1 
#14 cx601 8 
#13 alofisel 1 
#12 (‘stem cell*’ NEAR/5 (anal OR anus OR ano* OR peri*an* OR rect*) NEAR/5 (fistul* OR 
crohn*)):ti,ab 
30 
#11 #6 AND #10 467 
#10 #7 OR #8 OR #9 134,498 
#9 ((mesenchymal OR stroma*) NEAR/5 cell*):ti,ab 133,999 
#8 ‘mesenchymal stem cell transplantation’/mj/exp 5,642 
#7 ‘mesenchymal stroma cell’/mj/exp 4,673 
#6 #1 OR #2 OR #3 OR #4 OR #5 83,321 
#5 ‘crohn* fistula’ 16 
#4 crohn*:ti,ab 64,666 
#3 ‘crohn disease’/mj/exp 42,469 
#2 ((anal OR anus OR ano* OR peri*an* OR rect*) NEAR/5 fistul*):ti,ab 14,527 
#1 ‘anus fistula’/mj/exp 2,419 
 
 
Search strategy for Ovid Medline 
Search Date:13.12.2017 
No. Query Results Results 
1 exp Rectal Fistula/ 5,927 
2 ((anal or anus or ano* or peri?an* or rect*) adj5 fistul*).mp. 1,0217 
3 exp Crohn Disease/ 38,879 
4 Crohn*.mp. 54,313 
5 Crohn$2 fistula*.mp. 96 
6 1 or 2 or 3 or 4 or 5 62,897 
7 exp Mesenchymal Stromal Cells/ 30,630 
8 exp Mesenchymal Stem Cell Transplantation/ 9,983 
9 ((mesenchymal or stroma*) adj5 cell*).mp. 117,488 
10 7 or 8 or 9 117,488 
11 6 and 10 333 
12 (stem cell* adj5 ((anal or anus or ano or peri?an* or rect*) adj5 (fistul* or Crohn*))).mp. 21 
13 Alofisel.ti,ab. 0 
14 Cx?601.ti,ab. 14 
15 TiGenix.ti,ab. 3 
16 Living Medicines.ti,ab. 0 
17 11 or 12 or 13 or 14 or 15 or 16 346 
18 remove duplicates from 17 299 
 
  
 
